text:
Patent US5208020 - Cytotoxic agents comprising maytansinoids and their therapeutic use - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier diluent or excipient....http://www.google.com/patents/US5208020?utm_source=gb-gplus-sharePatent US5208020 - Cytotoxic agents comprising maytansinoids and their therapeutic useAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS5208020 APublication typeGrantApplication numberUS 07/911,380Publication dateMay 4, 1993Filing dateJul 13, 1992Priority dateOct 25, 1989Fee statusPaidAlso published asUS5416064Publication number07911380, 911380, US 5208020 A, US 5208020A, US-A-5208020, US5208020 A, US5208020AInventorsRavi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. BlattlerOriginal AssigneeImmunogen Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (19), Non-Patent Citations (8), Referenced by (823), Classifications (13), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetCytotoxic agents comprising maytansinoids and their therapeutic use
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3896111 *Feb 20, 1973Jul 22, 1975Research CorpAnsa macrolidesUS4137230 *Mar 15, 1978Jan 30, 1979Takeda Chemical Industries, Ltd.Method for the production of maytansinoidsUS4248870 *Oct 18, 1979Feb 3, 1981Takeda Chemical Industries, Ltd.Maytansinoids and useUS4256246 *Jun 26, 1979Mar 17, 1981Lkb-Produkter AbDevice for breaking a glass plate so as to obtain a sharp edgeUS4260608 *Nov 9, 1979Apr 7, 1981Takeda Chemical Industries, Ltd.Maytansinoids, pharmaceutical compositions thereof and methods of use thereofUS4263294 *Nov 13, 1979Apr 21, 1981Takeda Chemical Industries, Ltd.Maytansinoids, pharmaceutical compositions thereof and method of use thereofUS4264596 *Jul 23, 1980Apr 28, 1981Takeda Chemical Industries, Ltd.Maytansinoids, pharmaceutical compositions thereof and method of use thereofUS4294757 *Jan 15, 1980Oct 13, 1981Takeda Chemical Industries, Ltd20-O-AcylmaytansinoidsUS4307016 *May 27, 1980Dec 22, 1981Takeda Chemical Industries, Ltd.Demethyl maytansinoidsUS4308268 *May 28, 1980Dec 29, 1981Takeda Chemical Industries, Ltd.Maytansinoids, pharmaceutical compositions thereof and method of use thereofUS4308269 *Jun 6, 1980Dec 29, 1981Takeda Chemical Industries, Ltd.Maytansinoids, pharmaceutical compositions thereof and method of use thereofUS4309428 *Jul 23, 1980Jan 5, 1982Takeda Chemical Industries, Ltd.MaytansinoidsUS4313946 *Jan 27, 1981Feb 2, 1982The United States Of America As Represented By The Secretary Of AgricultureChemotherapeutically active maytansinoids from Trewia nudifloraUS4362663 *Sep 17, 1980Dec 7, 1982Takeda Chemical Industries, Ltd.Maytansinoid compoundUS4364866 *Sep 17, 1980Dec 21, 1982Takeda Chemical Industries, Ltd.MaytansinoidsUS4418064 *Sep 29, 1982Nov 29, 1983The United States Of America As Represented By The Secretary Of AgricultureChemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudoneUS4424219 *May 3, 1982Jan 3, 1984Takeda Chemical Industries, Ltd.9-Thiomaytansinoids and their pharmaceutical compositions and useEP0205326A2 *Jun 6, 1986Dec 17, 1986Immunomedics, Inc.Antibody conjugatesEP0376176A2 *Dec 22, 1989Jul 4, 1990Takeda Chemical Industries, Ltd.Bispecific monoclonal antibody, its production and use* Cited by examinerNon-Patent CitationsReference1 *Endo et al, Cancer Research 47; 1076 1080 (Feb. 15, 1987).2Endo et al, Cancer Research 47; 1076-1080 (Feb. 15, 1987).3 *Greenfield et al Cancer Research, 50: 6600 6607 Oct. 15, 1990.4Greenfield et al Cancer Research, 50: 6600-6607 Oct. 15, 1990.5 *Mueller et al, Bioconjugate Chem. 1: 325 330 (1990).6Mueller et al, Bioconjugate Chem. 1: 325-330 (1990).7Ravi V. J. Chari et al, "Immunoconjugates Containing Novel Maytensinoids: Promising Anticancer Drugs" (Cancer Research), Cambridge, Mass., pp. 127-131, (Jan. 1, 1992).8 *Ravi V. J. Chari et al, Immunoconjugates Containing Novel Maytensinoids: Promising Anticancer Drugs (Cancer Research), Cambridge, Mass., pp. 127 131, (Jan. 1, 1992).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5824805 *Dec 19, 1996Oct 20, 1998King; DaltonBranched hydrazone linkersUS6013480 *Aug 14, 1998Jan 11, 2000Immunex CorporationAntagonists of interleukin-15US6165466 *Aug 14, 1998Dec 26, 2000Immunex CorporationAntagonists of interleukin-15US6168783Aug 14, 1998Jan 2, 2001Immunex CorporationAntagonists of interleukin-15US6177079Nov 20, 1998Jan 23, 2001Immunex CorporationAntagonists of interleukin-15US6214345May 14, 1993Apr 10, 2001Bristol-Myers Squibb Co.Lysosomal enzyme-cleavable antitumor drug conjugatesUS6251392 *Oct 20, 1997Jun 26, 2001Epicyte Pharmaceuticals, Inc.Epithelial cell targeting agentUS6333410 *Aug 18, 2000Dec 25, 2001Immunogen, Inc.Process for the preparation and purification of thiol-containing maytansinoidsUS6368598Jul 6, 1998Apr 9, 2002Jcrt Radiation Oncology Support Services, Inc.Drug complex for treatment of metastatic prostate cancerUS6440419 *Oct 20, 1998Aug 27, 2002Epicyte Pharmaceutical, Inc.Epithelial cell targeting agentUS6441163 *May 31, 2001Aug 27, 2002Immunogen, Inc.Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsUS6570024Sep 12, 2001May 27, 2003Smithkline Beecham CorporationProcess and intermediatesUS6573074Apr 9, 2001Jun 3, 2003Smithkline Beecham PlcMethods for ansamitocin productionUS6667039 *Jul 28, 2000Dec 23, 2003Immunex CorporationCD30 ligandUS6716821Dec 21, 2001Apr 6, 2004Immunogen Inc.Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the sameUS6824780Oct 27, 2000Nov 30, 2004Genentech, Inc.Anti-tumor antibody compositions and methods of useUS6884874 *Mar 17, 2003Apr 26, 2005Smithkline Beecham CorporationProcess and intermediatesUS6914130 *Aug 14, 2001Jul 5, 2005Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS7008624May 25, 2000Mar 7, 2006Immunex CorporationAntagonists of interleukin-15US7067132Nov 6, 2002Jun 27, 2006Immuner Corp.Antagonists of interleukin-15US7097840Mar 16, 2001Aug 29, 2006Genentech, Inc.Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesUS7235240Sep 7, 2005Jun 26, 2007Amgen Inc.Antagonists of interleukin-15US7303749Sep 29, 2000Dec 4, 2007Immunogen Inc.Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsUS7361347Jul 1, 2005Apr 22, 2008Boehringer Ingelheim International GmbhCytotoxic CD44 antibody immunoconjugatesUS7368565 *Jun 5, 2002May 6, 2008Immunogen Inc.Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsUS7374762May 14, 2004May 20, 2008Immunogen, Inc.Drug conjugate compositionUS7432088Jan 19, 2005Oct 7, 2008Immunogen Inc.Methods for the production of ansamitocinsUS7435416Sep 8, 2004Oct 14, 2008Genetech, Inc.Anti-tumor antibody compositions and methods of useUS7494649Sep 14, 2006Feb 24, 2009Immunogen, Inc.Drug conjugate compositionUS7501120Sep 14, 2006Mar 10, 2009Immunogen, Inc.Drug conjugate compositionUS7511023 *Aug 14, 2002Mar 31, 2009Korea Institute Of Science And TechnologyAnticancer drug-chitosan complex forming self-aggregates and preparation method thereofUS7514080Sep 14, 2006Apr 7, 2009Immunogen, Inc.Drug conjugate compositionUS7527791Mar 31, 2005May 5, 2009Genentech, Inc.Humanized anti-TGF-beta antibodiesUS7528236Sep 2, 2005May 5, 2009Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforUS7531174Oct 23, 2003May 12, 2009Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS7557190Jul 7, 2009Xencor, Inc.Optimized proteins that target Ep-CAMUS7575748 *Jul 17, 2006Aug 18, 2009Genentech, Inc.Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesUS7582299 *Sep 20, 2004Sep 1, 2009Biogen Idec Ma Inc.Cripto-specific antibodiesUS7601354Jun 15, 2006Oct 13, 2009Immunogen Inc.Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsUS7674462Apr 30, 2007Mar 9, 2010Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS7687605Mar 2, 2007Mar 30, 2010Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforUS7700097Jun 28, 2004Apr 20, 2010Biogen Idec Ma Inc.Purification and preferential synthesis of binding moleculesUS7745391May 31, 2006Jun 29, 2010Compugen Ltd.Human thrombospondin polypeptideUS7749504Apr 11, 2007Jul 6, 2010Genentech, Inc.Anti-TAT188 antibodiesUS7754441Jul 13, 2010Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS7763434Jul 27, 2010Immunex CorporationAntagonists of interleukin-15US7767803Mar 7, 2006Aug 3, 2010Archemix Corp.Stabilized aptamers to PSMA and their use as prostate cancer therapeuticsUS7803915Sep 8, 2004Sep 28, 2010Genentech, Inc.Antibody compositions for the diagnosis and treatment of tumorUS7811572Aug 14, 2006Oct 12, 2010Immunogen, Inc.Process for preparing purified drug conjugatesUS7851432Jul 16, 2007Dec 14, 2010Immunogen Inc.Cytotoxic agents comprising new maytansinoidsUS7858330May 4, 2006Dec 28, 2010Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS7879369Feb 1, 2011Selvamedica, LlcCombretum laurifolium Mart. extract and methods of extracting and using such extractUS7888052Mar 31, 2009Feb 15, 2011Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS7888478Feb 15, 2011Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS7951546May 29, 2008May 31, 2011Genetech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS7981418 *Jul 19, 2011Genentech, Inc.Predicting response to a HER inhibitorUS7982012Mar 10, 2009Jul 19, 2011Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of cytomegalovirusUS7989598 *Aug 2, 2011Immunogen Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS8003763Dec 22, 2008Aug 23, 2011Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS8012482Apr 14, 2009Sep 6, 2011Genentech, Inc.Humanized anti-TGF-beta antibodiesUS8012485Feb 6, 2009Sep 6, 2011Immunogen, Inc.Drug conjugate compositionUS8012978Sep 6, 2011Immunogen, Inc.Prodrugs of CC-A1065 analogsUS8021661Sep 20, 2011Biogen Idec Ma Inc.Cripto binding moleculesUS8057796Nov 12, 2008Nov 15, 2011Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenzaUS8063187Nov 22, 2011Xencor, Inc.Methods and compositions for inhibiting CD32B expressing cellsUS8084026Dec 27, 2011Biogen Idec Ma Inc.Multispecific binding molecules comprising connecting peptidesUS8088378Jan 3, 2012Genetech Inc.Anti-CD79B antibodies and immunoconjugates and methods of useUS8088387 *Oct 8, 2004Jan 3, 2012Immunogen Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesUS8093357Jul 7, 2006Jan 10, 2012Xencor, Inc.Optimized Fc variants and methods for their generationUS8101720Jan 24, 2012Xencor, Inc.Immunoglobulin insertions, deletions and substitutionsUS8114402Mar 17, 2010Feb 14, 2012Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenzaUS8124082Feb 23, 2009Feb 28, 2012Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforUS8137669Aug 5, 2008Mar 20, 2012Immunogen, Inc.Elimination of heterogeneous or mixed cell population in tumorsUS8142784Mar 27, 2012Genentech, Inc.Antibody-drug conjugates and methodsUS8163736Jul 16, 2008Apr 24, 2012Sanofi-AventisCytotoxic agents comprising new tomaymycin derivativesUS8163888Apr 24, 2012Immunogen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS8198417 *Jun 12, 2012Immunogen Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS8226945Nov 4, 2010Jul 24, 2012Genentech, Inc.Antibodies and immunoconjugates and uses thereforUS8258100 *Jun 19, 2009Sep 4, 2012Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeLigand/lytic peptide methods of useUS8268309Sep 18, 2012Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of cytomegalovirusUS8287894Jul 27, 2005Oct 16, 2012Alchemia Oncology Pty LimitedHyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of diseaseUS8318907Nov 27, 2012Xencor, Inc.Fc variants with altered binding to FcRnUS8324351Dec 4, 2012Xencor, Inc.Fc variants with altered binding to FcRnUS8337856 *Dec 25, 2012Immunogen, Inc.Methods of treatment using anti-ERBB antibody-maytansinoid conjugatesUS8338574Dec 25, 2012Xencor, Inc.FC variants with altered binding to FCRNUS8367805Dec 22, 2008Feb 5, 2013Xencor, Inc.Fc variants with altered binding to FcRnUS8383122Feb 26, 2013Immunogen, Inc.Process for preparing purified drug conjugatesUS8388955Jun 15, 2007Mar 5, 2013Xencor, Inc.Fc variantsUS8388960Sep 9, 2011Mar 5, 2013Immunogen Inc.Elimination of heterogeneous or mixed cell population in tumorsUS8388973Dec 30, 2010Mar 5, 2013Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS8388993Mar 5, 2013Alchemia Oncology Pty LimitedHyaluronan-chemotherapeutic agent formulations for the treatment of colon cancerUS8394607Jul 26, 2012Mar 12, 2013Genentech, Inc.Anti-CD22 antibodies and immunoconjugates and methods of useUS8404678Mar 26, 2013SanofiCytotoxic agents comprising new tomaymycin derivatives and their therapeutic useUS8410250Apr 2, 2013Genentech, Inc.Anti-FGFR3 antibodies and methods using sameUS8435528 *Jul 16, 2007May 7, 2013Immunogen, Inc.Cytotoxic agents comprising new maytansinoidsUS8460667Jul 13, 2007Jun 11, 2013SanofiEPHA2 receptor antagonist antibodiesUS8460671Jun 11, 2013Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenzaUS8524865May 29, 2007Sep 3, 2013Genentech, Inc.Antibodies and immunoconjugates and uses thereforUS8545850Nov 5, 2010Oct 1, 2013Genentech, Inc.Anti-CD79B antibodies and immunoconjugates and methods of useUS8546543Oct 12, 2011Oct 1, 2013Xencor, Inc.Fc variants that extend antibody half-lifeUS8563509Oct 29, 2007Oct 22, 2013Immunogen Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS8603473Apr 9, 2008Dec 10, 2013Biogen Idec Ma Inc.Modified binding molecules comprising connecting peptidesUS8603483Nov 30, 2005Dec 10, 2013Janssen Biotech, Inc.Anti-integrin immunoconjugates, methods and usesUS8609101Apr 23, 2010Dec 17, 2013Theraclone Sciences, Inc.Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodiesUS8623354Sep 4, 2006Jan 7, 2014Alchemia Oncology Pty LimitedTherapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatmentUS8637641Jul 29, 2011Jan 28, 2014Xencor, Inc.Antibodies with modified isoelectric pointsUS8642555 *Mar 9, 2010Feb 4, 2014Ktb Tumorforschungsgesellschaft MbhProdrugsUS8652479Mar 21, 2008Feb 18, 2014Genentech, Inc.Antibody-drug conjugates and methodsUS8663643Mar 10, 2009Mar 4, 2014Genentech, Inc.Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of useUS8668910Sep 30, 2010Mar 11, 2014SanofiAntibodies that specifically bind to the EphA2 receptorUS8673303Aug 19, 2011Mar 18, 2014Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS8679490Nov 7, 2006Mar 25, 2014Genentech, Inc.Binding polypeptides with diversified and consensus VH/VL hypervariable sequencesUS8685920Jul 8, 2011Apr 1, 2014Immunogen Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS8691531Nov 28, 2011Apr 8, 2014Genentech, Inc.Anti-CD79B antibodies and immunoconjugates and methods of useUS8710189Oct 16, 2012Apr 29, 2014Genentech, Inc.Anti-FGFR3 antibodies and methods using sameUS8722857Jan 14, 2009May 13, 2014Genentech, Inc.Anti-CD79B antibodies and immunoconjugates and methods of useUS8728480Nov 10, 2011May 20, 2014Genetech, Inc.Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereofUS8741970Dec 14, 2011Jun 3, 2014Alchemia Oncology Pty LimitedComposition and method for the enhancement of the efficacy of drugsUS8759491Oct 18, 2010Jun 24, 2014Genentech, Inc.Modulators of hepatocyte growth factor activatorUS8771685Dec 22, 2010Jul 8, 2014F. Hoffmann-La Roche AgAnti-BV8 antibodies and uses thereofUS8771966Dec 3, 2012Jul 8, 2014Genentech, Inc.Immuno-PET imaging of antibodies and immunoconjugates and uses thereforUS8779100Jan 12, 2012Jul 15, 2014Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforUS8790649Oct 28, 2011Jul 29, 2014Immunogen, Inc.EGFR-binding molecules and immunoconjugates thereofUS8795673 *Mar 29, 2012Aug 5, 2014Immunogen, Inc.Preparation of maytansinoid antibody conjugates by a one-step processUS8802820Oct 31, 2007Aug 12, 2014Xencor, Inc.Fc variants with altered binding to FcRnUS8822651Aug 28, 2012Sep 2, 2014Theraclone Sciences, Inc.Human rhinovirus (HRV) antibodiesUS8835133Mar 7, 2013Sep 16, 2014Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforUS8840898 *Apr 16, 2007Sep 23, 2014Biotest AgImmunoconjugates targeting syndecan-1 expressing cells and use thereofUS8841425Mar 9, 2011Sep 23, 2014Immunogen, Inc.Cytotoxic agents comprising new maytansinoidsUS8852586Feb 1, 2010Oct 7, 2014Xencor, Inc.Fc variants with altered binding to FcRnUS8852594Jun 1, 2012Oct 7, 2014Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of cytomegalovirus infectionsUS8853369Dec 7, 2012Oct 7, 2014Genentech, Inc.Anti-Axl antibodies and methods of useUS8853376Sep 16, 2011Oct 7, 2014Archemix LlcStabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsUS8858948May 20, 2010Oct 14, 2014Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenzaUS8877706Mar 15, 2013Nov 4, 2014Bio-Thera Solutions Ltd., Co.Maytansinoid derivativesUS8883973Feb 1, 2010Nov 11, 2014Xencor, Inc.Fc variants with altered binding to FcRnUS8889855Mar 15, 2013Nov 18, 2014Bio-Thera Solutions Ltd., Co.Preparation of maytansinoid estersUS8900549Nov 2, 2009Dec 2, 2014The General Hospital CorporationCompositions and methods for delivering a substance to a biological targetUS8900590Aug 12, 2011Dec 2, 2014Theraclone Sciences, Inc.Anti-hemagglutinin antibody compositions and methods of use thereofUS8916160Feb 14, 2012Dec 23, 2014Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenzaUS8933205Feb 25, 2013Jan 13, 2015Immunogen, Inc.Process for preparing purified drug conjugatesUS8937052Jul 27, 2006Jan 20, 2015Alchemia Oncology Pty LimitedTherapeutic protocols using hyaluronanUS8937158Aug 20, 2007Jan 20, 2015Xencor, Inc.Fc variants with increased affinity for FcγRIIcUS8940302Oct 9, 2012Jan 27, 2015Genentech, Inc.Predicting response to a HER inhibitorUS8952147Dec 20, 2011Feb 10, 2015SanofiConjugates, preparation thereof, and therapeutic use thereofUS8957187Dec 1, 2006Feb 17, 2015Genentech, Inc.Binding polypeptides and uses thereofUS8968741Feb 6, 2013Mar 3, 2015Genentech, Inc.Anti-CD22 antibodies and immunoconjugates and methods of useUS8969526Mar 27, 2012Mar 3, 2015Roche Glycart AgAntibody Fc variantsUS8987424 *Apr 13, 2008Mar 24, 2015Immunogen, Inc.CA6 antigen-specific cytotoxic conjugate and methods of using the sameUS8992924May 17, 2011Mar 31, 2015Biogen Idec Ma Inc.Anti-ανβ6 antibodies and uses thereofUS8999327Dec 7, 2010Apr 7, 2015Hoffman-La Roche Inc.Antibodies against human CSF-1R and uses thereofUS9000132Jul 31, 2013Apr 7, 2015Diadexus, Inc.Lipoprotein-associated phospholipase A2 antibody compositions and methods of useUS9011864Dec 23, 2008Apr 21, 2015Biotest AgMethod of decreasing cytotoxic side-effects and improving efficacy of immunoconjugatesUS9023356Mar 14, 2008May 5, 2015Ludwig Institute For Cancer Research LtdTreatment method using EGFR antibodies and SRC inhibitors and related formulationsUS9040041Jun 4, 2010May 26, 2015Xencor, Inc.Modified FC moleculesUS9056910Apr 30, 2013Jun 16, 2015Genentech, Inc.Anti-PMEL17 antibodies and immunoconjugatesUS9056914Jan 25, 2013Jun 16, 2015SanofiAnticancer derivatives, preparation thereof and therapeutic use thereofUS9062113Nov 10, 2008Jun 23, 2015Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS9066919Aug 5, 2005Jun 30, 2015Alchemia Oncology Pty LimitedHyaluronan as a chemo-sensitizer in the treatment of cancerUS9072798Feb 17, 2010Jul 7, 2015Ludwig Institute For Cancer Research Ltd.Specific binding proteins and uses thereofUS9073998Mar 2, 2009Jul 7, 2015Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS9079960Aug 24, 2012Jul 14, 2015Xencor, Inc.Methods and compositions for inhibiting CD32B expressing cellsUS9085621Sep 9, 2011Jul 21, 2015Apexigen, Inc.Anti-IL-1β antibodiesUS9085624Nov 10, 2008Jul 21, 2015Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS9085630Jun 6, 2011Jul 21, 2015Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS9090693Jan 24, 2008Jul 28, 2015Dana-Farber Cancer InstituteUse of anti-EGFR antibodies in treatment of EGFR mutant mediated diseaseUS9096672Mar 2, 2009Aug 4, 2015Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS9102724Aug 9, 2012Aug 11, 2015Omeros CorporationAnti-FZD10 monoclonal antibodies and methods for their useUS9114179Aug 3, 2006Aug 25, 2015Immunogen, Inc.Immunoconjugate formulationsUS9120858Jul 20, 2012Sep 1, 2015The Research Foundation Of State University Of New YorkAntibodies to the B12-transcobalamin receptorUS9125896Mar 13, 2013Sep 8, 2015Immunogen, Inc.EGFR-binding molecules and immunoconjugates thereofUS9156915Apr 26, 2013Oct 13, 2015Thomas Jefferson UniversityAnti-GCC antibody moleculesUS9161977Feb 7, 2013Oct 20, 2015F. Hoffmann-La Roche AgAnti-FGFR3 antibodies and methods using sameUS9169323Mar 3, 2011Oct 27, 2015Hoffmann-La Roche Inc.Antibodies against human CSF-1RUS9175089Mar 29, 2013Nov 3, 2015Genentech, Inc.Anti-LGR5 antibodies and immunoconjugatesUS9192667Apr 21, 2014Nov 24, 2015Hoffmann-La Roche Inc.Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonistUS9193766Oct 12, 2012Nov 24, 2015Genentech, Inc.Peptide inhibitors of BACE1US9200079Nov 14, 2005Dec 1, 2015Xencor, Inc.Fc variants with altered binding to FcRnUS9221910Mar 3, 2011Dec 29, 2015Hoffmann-La Roche Inc.Antibodies against human CSF-1RUS9221914Dec 23, 2008Dec 29, 2015Biotest AgAgents targeting CD138 and uses thereofUS9233171Nov 21, 2012Jan 12, 2016Immunogen, Inc.Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugateUS9238690Oct 28, 2011Jan 19, 2016Immunogen, Inc.Non-antagonistic EGFR-binding molecules and immunoconjugates thereofUS9238878Feb 16, 2010Jan 19, 2016Redwood Bioscience, Inc.Aldehyde-tagged protein-based drug carriers and methods of useUS9260523Nov 21, 2011Feb 16, 2016Xencor, Inc.Methods and compositions for inhibiting CD32b expressing cellsUS9260524Dec 11, 2012Feb 16, 2016Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereofUS9266948May 29, 2014Feb 23, 2016Genentech, Inc.Anti-Bv8 antibodies and uses thereofUS9266961Jun 14, 2013Feb 23, 2016Genentech, Inc.Anti-PCSK9 antibodies, formulations, dosing, and methods of useUS9273142Oct 10, 2013Mar 1, 2016Siamab Therapeutics, Inc.Glycan-interacting compoundsUS9283276Aug 14, 2008Mar 15, 2016Ludwig Institute For Cancer Research Ltd.Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereofUS9289512 *Jun 21, 2012Mar 22, 2016Immunogen, Inc.Maytansinoid derivatives with peptide linker and conjugates thereofUS9296785Apr 16, 2010Mar 29, 2016Wake Forest University Health SciencesIL-13 receptor binding peptidesUS9302015Aug 20, 2014Apr 5, 2016Regeneron Pharmaceuticals, Inc.Anti-PRLR antibodies and methods for killing PRLR-expressing cellsUS9314536Mar 15, 2013Apr 19, 2016Bio-Thera Solutions, Ltd., Co.Compounds and methods for the treatment of EGFR positive diseasesUS9345786Mar 15, 2013May 24, 2016Bio-Thera Solutions, Ltd., Co.Maytansinoid derivativesUS9370584Oct 26, 2010Jun 21, 2016Immunogen Inc.CA6 antigen-specific cytotoxic conjugate and methods of using the sameUS9376500Dec 3, 2013Jun 28, 2016Immunogen, Inc.Conjugation methodsUS9382323Mar 31, 2010Jul 5, 2016Roche Glycart AgMultispecific antibodies comprising full length antibodies and single chain fab fragmentsUS9387261Dec 23, 2008Jul 12, 2016Biotest AgImmunoconjugates targeting CD138 and uses thereofUS9387265Sep 8, 2014Jul 12, 2016The General Hospital CorporationPlectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinomaUS9394366Nov 29, 2012Jul 19, 2016Xencor, Inc.Methods and compositions for inhibiting CD32B expressing cellsUS9399676Jul 9, 2015Jul 26, 2016Scholar Rock, Inc.Compositions and methods for growth factor modulationUS9416194Jan 21, 2016Aug 16, 2016Siamab Therapeutics, Inc.Glycan-interacting compoundsUS9428543Jun 24, 2014Aug 30, 2016Immunogen, Inc.Preparation of maytansinoid antibody conjugates by a one-step processUS9446146Dec 23, 2008Sep 20, 2016Biotest AgMethods and agents for improving targeting of CD138 expressing tumor cellsUS9464139Aug 28, 2014Oct 11, 2016Amgen Inc.GITR antigen binding proteins and methods of use thereofUS9465029Apr 29, 2015Oct 11, 2016Glaxo Group LimitedMethods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activityUS20020161199 *Aug 23, 2001Oct 31, 2002Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20030055224 *Aug 14, 2001Mar 20, 2003Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20030055226 *Jun 5, 2002Mar 20, 2003Immunogen, Inc.Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsUS20030103985 *May 17, 2002Jun 5, 2003Boehringer Ingelheim International GmbhCytotoxic CD44 antibody immunoconjugatesUS20030157669 *Mar 4, 2003Aug 21, 2003Smithkline Beecham PlcAnsamitocinsUS20040009149 *Feb 27, 2003Jan 15, 2004Altman John D.Multimeric binding complexesUS20040014980 *Mar 17, 2003Jan 22, 2004Smithkline Beecham PlcProcess and intermediatesUS20040022727 *Jun 18, 2003Feb 5, 2004Martin StantonAptamer-toxin molecules and methods for using sameUS20040138152 *Aug 14, 2002Jul 15, 2004Kwon Ick ChanAnticancer drug-chitosan complex forming self-aggregates and preparation method thereofUS20040146940 *Oct 23, 2003Jul 29, 2004Michele Sanicola-NadelCripto blocking antibodies and uses thereofUS20040235068 *Sep 4, 2002Nov 25, 2004Levinson Arthur D.Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disordersUS20040241174 *May 14, 2004Dec 2, 2004Immunogen, Inc.Drug conjugate compositionUS20040253587 *Nov 6, 2002Dec 16, 2004Immunex CorporationAntagonists of interleukin-15US20050036942 *Sep 8, 2004Feb 17, 2005Genentech, Inc.Anti-tumor antibody compositions and methods of useUS20050106644 *Sep 8, 2004May 19, 2005Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20050107595 *Sep 10, 2004May 19, 2005Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20050112130 *Nov 5, 2004May 26, 2005Bhat Neelima M.Enhanced B cell cytotoxicity of CDIM binding antibodyUS20050113571 *Nov 30, 2004May 26, 2005Smithkline Beecham CorporationProcess for preparing maytansinolUS20050142133 *Dec 3, 2004Jun 30, 2005Xencor, Inc.Optimized proteins that target the epidermal growth factor receptorUS20050159588 *Dec 21, 2004Jul 21, 2005Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20050159591 *Dec 21, 2004Jul 21, 2005Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20050163782 *Jun 28, 2004Jul 28, 2005Biogen Idec Ma Inc.Modified binding molecules comprising connecting peptidesUS20050163783 *Jun 28, 2004Jul 28, 2005Biogen Idec Ma Inc.Purification and preferential synthesis of binding moleculesUS20050169933 *Oct 8, 2004Aug 4, 2005Immunogen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesUS20050170464 *Mar 2, 2005Aug 4, 2005Genentech, Inc.Prokaryotically produced antibodies and use thereofUS20050170475 *Jan 19, 2005Aug 4, 2005ImmunogenMethods for the production of ansamitocinsUS20050226869 *Dec 21, 2004Oct 13, 2005Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS20050227328 *May 13, 2005Oct 13, 2005Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the sameUS20050233948 *Apr 8, 2005Oct 20, 2005Beth Israel Deaconess Medical CenterDrug complex for treatment of metastatic prostate cancerUS20050238650 *Nov 16, 2004Oct 27, 2005Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS20050244413 *Jun 30, 2005Nov 3, 2005Guenther AdolfCompositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agentsUS20050255117 *Sep 20, 2004Nov 17, 2005Biogen Idec Inc.Cripto-specific antibodiesUS20050260634 *Mar 21, 2005Nov 24, 2005Genentech, Inc.Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumorUS20050267069 *Jul 27, 2005Dec 1, 2005Tracey BrownHyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of diseaseUS20050271672 *Jul 1, 2005Dec 8, 2005Guenther AdolfCytotoxic CD44 antibody immunoconjugatesUS20050276802 *Mar 31, 2005Dec 15, 2005Genentech, Inc.Humanized anti-TGF-beta antibodiesUS20050276812 *May 31, 2005Dec 15, 2005Genentech, Inc.Antibody-drug conjugates and methodsUS20060002930 *Apr 15, 2005Jan 5, 2006Genentech, Inc.Treatment of disordersUS20060045877 *Oct 29, 2004Mar 2, 2006Goldmakher Viktor SImmunoconjugates targeting syndecan-1 expressing cells and use thereofUS20060057103 *Sep 7, 2005Mar 16, 2006Grabstein Kenneth HAntagonists of interleukin-15US20060068405 *Jan 27, 2005Mar 30, 2006Alex DiberMethods and systems for annotating biomolecular sequencesUS20060093601 *Sep 2, 2005May 4, 2006Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforUS20060127407 *Nov 30, 2005Jun 15, 2006Qiming ChenAnti-integrin immunoconjugates, methods and usesUS20060177446 *Nov 29, 2005Aug 10, 2006Genentech, Inc.Polypeptides that bind an anti-tissue factor antibody and uses thereofUS20060178342 *Aug 5, 2005Aug 10, 2006Tracey BrownHyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of diseaseUS20060182750 *Feb 10, 2006Aug 17, 2006Immunogen, Inc.Process for preparing stable drug conjugatesUS20060216232 *Dec 21, 2005Sep 28, 2006Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS20060233811 *Jun 15, 2006Oct 19, 2006Immunogen Inc.Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsUS20060233814 *Apr 14, 2006Oct 19, 2006Immunogen Inc.Elimination of heterogeneous or mixed cell population in tumorsUS20060246542 *Feb 9, 2006Nov 2, 2006Genentech, Inc.System for antibody expression and assemblyUS20060263395 *May 1, 2006Nov 23, 2006Meditech Research LimitedHyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of diseaseUS20070009539 *Sep 14, 2006Jan 11, 2007Immunogen, Inc.Drug conjugate compositionUS20070009540 *Sep 14, 2006Jan 11, 2007Immunogen, Inc.Drug conjugate compositionUS20070009541 *Sep 14, 2006Jan 11, 2007Immunogen, Inc.Drug conjugate compositionUS20070020725 *May 22, 2006Jan 25, 2007Genentech, Inc.Prokaryotically produced antibodies and uses thereofUS20070031402 *Aug 3, 2006Feb 8, 2007Immunogen Inc.Immunoconjugate formulationsUS20070031901 *Jul 14, 2006Feb 8, 2007Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20070048314 *Aug 14, 2006Mar 1, 2007Immunogen, Inc.Process for preparing purified drug conjugatesUS20070048326 *Oct 4, 2006Mar 1, 2007Genentech, Inc.Compositions and Methods for the Diagnosis and Treatment of TumorUS20070065909 *Feb 9, 2006Mar 22, 2007Genentech, Inc.Prokaryotically produced antibodies and uses thereofUS20070082337 *Jan 27, 2005Apr 12, 2007Compugen Ltd.Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered therebyUS20070083334 *May 31, 2006Apr 12, 2007Compugen Ltd.Methods and systems for annotating biomolecular sequencesUS20070117124 *Sep 29, 2006May 24, 2007Genentech, Inc.Achaete-Scute Like-2 Polypeptides and Encoding Nucleic Acids and Methods for the Diagnosis and Treatment of TumorUS20070135620 *May 17, 2006Jun 14, 2007Xencor, Inc.Fc variants with altered binding to FcRnUS20070160597 *Jul 7, 2006Jul 12, 2007Xencor, Inc.Optimized Fc variants and methods for their generationUS20070183971 *Apr 16, 2007Aug 9, 2007Biotest AgImmunoconjugates targeting syndecan-1 expressing cells and use thereofUS20070202552 *Dec 1, 2006Aug 30, 2007Genentech, Inc.Binding Polypeptides and Uses ThereofUS20070207142 *Aug 3, 2006Sep 6, 2007Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS20070224664 *Jan 25, 2007Sep 27, 2007Genentech, Inc.System for Antibody Expression and AssemblyUS20070231329 *Jun 15, 2007Oct 4, 2007Xencor, Inc.Fc Variants Having Increased Affinity for FcyRIIbUS20070237764 *Dec 1, 2006Oct 11, 2007Genentech, Inc.Binding polypeptides with restricted diversity sequencesUS20070264266 *Jul 16, 2007Nov 15, 2007Immunogen Inc.Cytotoxic agents comprising new maytansinoidsUS20070269446 *Nov 28, 2006Nov 22, 2007Genentech, Inc.Compositions and Methods for the Treatment of Tumor of Hematopoietic OriginUS20070269447 *Jul 16, 2007Nov 22, 2007Immunogen, Inc.Cytotoxic agents comprising new maytansinoidsUS20080025971 *Mar 2, 2007Jan 31, 2008Sherman FongHumanized anti-beta7 antagonists and uses thereforUS20080050310 *May 29, 2007Feb 28, 2008Genentech, Inc.Antibodies and immunoconjugates and uses thereforUS20080051563 *Aug 20, 2007Feb 28, 2008Xencor, Inc.Fc Variants with Increased Affinity for FcyRIIcUS20080114153 *Oct 29, 2007May 15, 2008Immunogen. Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS20080124331 *Apr 11, 2007May 29, 2008Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorUS20080145374 *Oct 29, 2007Jun 19, 2008Immunogen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS20080154025 *Aug 20, 2007Jun 26, 2008Xencor, Inc.Fc Variants with Increased Affinity for FcyRIIcUS20080161541 *Aug 20, 2007Jul 3, 2008Xencor, Inc.Fc Variants with Increased Affinity for FcyRIIcUS20080166294 *Aug 1, 2006Jul 10, 2008Genentech, Inc.Compositions and methods for the treatment of tumor of hematopoietic originUS20080166341 *Apr 30, 2007Jul 10, 2008Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS20080171040 *Mar 21, 2008Jul 17, 2008Genentech, Inc.Antibody-drug conjugates and methodsUS20080171856 *Oct 29, 2007Jul 17, 2008Immunogen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS20080171865 *Oct 29, 2007Jul 17, 2008Immunogen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesUS20080226659 *Dec 3, 2007Sep 18, 2008Sharon EricksonMethods of treatment using anti-erbb antibody-maytansinoid conjugatesUS20090010920 *Jun 15, 2007Jan 8, 2009Xencor, Inc.Fc Variants Having Decreased Affinity for FcyRIIbUS20090011060 *Feb 15, 2008Jan 8, 2009Peter KoepkeCampsiandra angustifolia extract and methods of extracting and using such extractUS20090017140 *Feb 18, 2008Jan 15, 2009Peter KoepkeMaytenus abenfolia extract and methods of extracting and using such extractUS20090017473 *May 29, 2008Jan 15, 2009Gretchen FrantzCompositions and methods for the diagnosis and treatment of tumorUS20090023602 *Jan 16, 2008Jan 22, 2009Genentech, Inc.Binding polypeptides with restricted diversity sequencesUS20090028821 *Sep 4, 2008Jan 29, 2009Sanofi-AventisProdrugs of cc-a1065 analogsUS20090028856 *Jul 15, 2008Jan 29, 2009Genentech, Inc.Anti-CD79B Antibodies and Immunoconjugates and Methods of UseUS20090035395 *Feb 18, 2008Feb 5, 2009Peter KoepkeSpondias mombin l. extract and methods of extracting and using such extractUS20090036431 *Jul 16, 2008Feb 5, 2009Sanofi-AventisCytotoxic Agents Comprising New Tomaymycin DerivativesUS20090041758 *Apr 9, 2008Feb 12, 2009Biogen Idec Ma Inc.Modified binding molecules comprising connecting peptidesUS20090041770 *Oct 31, 2007Feb 12, 2009Chamberlain Aaron KeithFc VARIANTS WITH ALTERED BINDING TO FcRnUS20090042291 *May 30, 2008Feb 12, 2009Xencor, Inc.Optimized Fc variantsUS20090053226 *Mar 27, 2008Feb 26, 2009Craig CrowleyCompositions and methods for the treatment of tumor of hematopoietic originUS20090053240 *Jan 25, 2008Feb 26, 2009Xencor, Inc.Novel Immunoglobulin Insertions, Deletions and SubstitutionsUS20090054537 *Jul 27, 2006Feb 26, 2009Alchemia Oncoloogy Pty LimitedTherapeutic protocols using hyaluronanUS20090068202 *Jul 15, 2008Mar 12, 2009Genentech, Inc.Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of UseUS20090074891 *Feb 18, 2008Mar 19, 2009Peter KoepkeCombretum laurifolium mart. extract and methods of extracting and using such extractUS20090075279 *May 29, 2008Mar 19, 2009Gretchen FrantzCompositions and methods for the diagnosis and treatment of tumorUS20090076263 *Aug 5, 2008Mar 19, 2009Immunogen Inc.Elimination of heterogeneous or mixed cell population in tumorsUS20090099336 *Apr 13, 2008Apr 16, 2009Immunogen Inc.CA6 Antigen-Specific Cytotoxic Conjugate and Methods of Using the SameUS20090105172 *Mar 7, 2006Apr 23, 2009Diener John LStabilized Aptamers to PSMA and Their Use as Prostate Cancer TherapeuticsUS20090136485 *May 30, 2008May 28, 2009Xencor, Inc.Methods and compositions for inhibiting CD32B expressing cellsUS20090142259 *May 9, 2007Jun 4, 2009Genentech, Inc.Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumorsUS20090142361 *Feb 6, 2009Jun 4, 2009Immunogen, Inc.Drug conjugate compositionUS20090155282 *Nov 10, 2008Jun 18, 2009Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS20090156790 *Nov 10, 2008Jun 18, 2009Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS20090162380 *Jul 5, 2007Jun 25, 2009Scott GlaserMultispecific binding molecules comprising connecting peptidesUS20090163699 *Dec 22, 2008Jun 25, 2009Chamberlain Aaron KeithFc VARIANTS WITH ALTERED BINDING TO FcRnUS20090169570 *Dec 23, 2008Jul 2, 2009Benjamin DaelkenMethods and agents for improving targeting of cd138 expressing tumor cellsUS20090175863 *Dec 23, 2008Jul 9, 2009Elmar KrausAgents targeting cd138 and uses thereofUS20090175887 *Mar 2, 2009Jul 9, 2009Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS20090181038 *Dec 23, 2008Jul 16, 2009Gregor SchulzMethod of decreasing cytotoxic side-effects and improving efficacy of immunoconjugatesUS20090202536 *Dec 2, 2008Aug 13, 2009Genentech, Inc.Antibody-drug conjugates and methodsUS20090215991 *Aug 20, 2007Aug 27, 2009Xencor, Inc.Optimized Fc Variants and methods for their generationUS20090226433 *Nov 12, 2008Sep 10, 2009Spaltudaq Corp.Compositions and methods for the therapy and diagnosis of influenzaUS20090226437 *Feb 23, 2009Sep 10, 2009Sherman FongHumanized anti-beta7 antagonists and uses thereforUS20090232810 *Dec 23, 2008Sep 17, 2009Elmar KrausImmunoconjugates targeting cd138 and uses thereofUS20090240038 *Mar 2, 2009Sep 24, 2009Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofUS20090269345 *Dec 22, 2006Oct 29, 2009Rong FanCLN248 Antibody Compositions and Methods of UseUS20090285818 *Nov 19, 2009Biogen Idec Ma Inc.Cripto Blocking Antibodies and Uses ThereofUS20090286246 *Nov 19, 2009Wintherix LlcMethods for Identifying Compounds that Affect Expression of Cancer-Related Protein IsoformsUS20090286265 *Nov 19, 2009Biogen Idec Ma Inc.Cripto Blocking Antibodies And Uses ThereofUS20090306012 *Jun 11, 2009Dec 10, 2009Alchemia Oncology Pty LimitedTherapeutic protocolsUS20090324490 *Feb 23, 2009Dec 31, 2009Belinda CaimsCompositions and methods for the diagnosis and treatment of tumorUS20090324592 *Dec 31, 2009Belinda CaimsCompositions and methods for the diagnosis and treatment of tumorUS20090324613 *Mar 10, 2009Dec 31, 2009Spaltudaq CorporationCompositions and Methods for the Therapy and Diagnosis of CytomegalovirusUS20100008906 *Jan 14, 2010Scott GlaserCripto binding moleculesUS20100015723 *Jan 21, 2010Amgen Inc.Antagonists of Interleukin-15US20100016227 *Jun 19, 2009Jan 21, 2010Board Of Supervisors Of Louisiana State University And Agricultural And Mechnical CollegeLigand/lytic peptide compositions and methods of useUS20100047257 *Jul 13, 2007Feb 25, 2010Sanofi-AventisAntagonist antibody for the treatment of cancerUS20100136033 *Oct 30, 2009Jun 3, 2010Immunogen, Inc.METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATESUS20100158903 *Sep 16, 2009Jun 24, 2010Craig SmithMethods for treating progressive multiple sclerosisUS20100202962 *Aug 12, 2010Biogen Idec Ma Inc.Cripto blocking antibodies and uses thereofUS20100204454 *Feb 1, 2010Aug 12, 2010Xencor, Inc.Fc Variants with altered binding to FcRnUS20100215669 *Jan 14, 2009Aug 26, 2010Genentech, Inc.Anti-cd79b antibodies and immunoconjugates and methods of useUS20100234572 *Feb 1, 2010Sep 16, 2010Xencor, Inc.Fc Variants with altered binding to FcRnUS20100234573 *Sep 16, 2010Xencor, Inc.Fc Variants with altered binding to FcRnUS20100234575 *Sep 16, 2010Xencor, Inc.Fc variants with altered binding to fcrnUS20100247531 *Sep 30, 2010Genentech, Inc.Anti-fgfr3 antibodies and methods using sameUS20100255508 *May 18, 2009Oct 7, 2010Thomas Richard GelzleichterUse of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsUS20100291075 *Nov 18, 2010Theraclone Sciences, Inc.Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing AntibodiesUS20100291114 *Mar 24, 2010Nov 18, 2010Genentech, Inc.Crystal structures and methods using sameUS20100311954 *Mar 15, 2010Dec 9, 2010Xencor, Inc.Optimized Proteins that Target Ep-CAMUS20100316656 *Jan 19, 2010Dec 16, 2010Sanofi-AventisCytotoxic agents comprising new tomaymycin derivatives and their therapeutic useUS20110021744 *Oct 8, 2010Jan 27, 2011Immunogen, Inc.Process for preparing purified drug conjugatesUS20110033476 *Jun 7, 2010Feb 10, 2011Theraclone Sciences Inc.Compositions and methods for the therapy and diagnosis of influenzaUS20110042260 *Aug 12, 2010Feb 24, 2011Craig CrowleyCompositions and methods for the treatment of tumor of hematopoietic originUS20110045005 *Feb 24, 2011Craig CrowleyCompositions and methods for the treatment of tumor of hematopoietic originUS20110052501 *Feb 1, 2009Mar 3, 2011Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologicsUS20110070243 *Mar 24, 2011Craig CrowleyCompositions and methods for the treatment of tumor of hematopoieticUS20110091477 *Apr 21, 2011Genentech, Inc.Modulators of hepatocyte growth factor activatorUS20110097345 *Apr 28, 2011Immunogen Inc.Novel dosing regimen and method of treatmentUS20110123530 *Mar 31, 2009May 26, 2011Arron Joseph RCompositions and methods for treating and diagnosing asthmaUS20110135667 *Nov 5, 2010Jun 9, 2011Genentech, Inc.Anti-cd79b antibodies and immunoconjugates and methods of useUS20110142859 *Nov 4, 2010Jun 16, 2011Genentech, Inc.Antibodies and immunoconjugates and uses thereforUS20110158991 *Jun 30, 2011Immunogen Inc.Cytotoxic agents comprising new maytansinoidsUS20110165156 *Jul 7, 2011Nikolaos DimoudisAntibodies against human csf-1r and uses thereofUS20110166319 *Dec 22, 2010Jul 7, 2011Immunogen, Inc.Process for preparing purified drug conjugatesUS20110177064 *Jul 21, 2011Immunogen, Inc.Compositions and Methods for Treatment of Ovarian CancerUS20110206658 *Aug 25, 2011Craig CrowleyCompositions and methods for the treatment of tumor of hematopoietic originUS20120094892 *Mar 9, 2010Apr 19, 2012Ktb Tumorforschungsgesellschaft MbhProdrugsUS20120253021 *Oct 4, 2012Immunogen, Inc.Preparation of maytansinoid antibody conjugates by a one-step processUS20130029900 *Jun 21, 2012Jan 31, 2013Immunogen, Inc.Novel maytansinoid derivatives with peptide linker and conjugates thereofUS20130108620 *Nov 28, 2011May 2, 2013Genentech, Inc.Methods of treatment using anti-erbb antibody-maytansinoid conjugatesUS20140212411 *Sep 19, 2013Jul 31, 2014Genentech, Inc.Methods of treatment using anti-erbb antibody-maytansinoid conjugatesUS20150110816 *Jun 4, 2014Apr 23, 2015Genentech, Inc.Methods of treatment using anti-erbb antibody-maytansinoid conjugatesUSRE39151Apr 10, 2003Jun 27, 2006Immunogen, Inc.Process for the preparation and purification of thiol-containing maytansinoidsUSRE43899Jan 1, 2013Immunogen Inc.Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsUSRE44681Apr 16, 2013Dec 31, 2013Biogen Idec Ma Inc.Compositions and methods for inhibiting growth of SMAD4-deficient cancersUSRE44704Sep 13, 2012Jan 14, 2014Immunogen Inc.Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsCN101374545BApr 14, 2006Mar 28, 2012免疫基因公司Elimination of heterogeneous or mixed cell population in tumorsCN103254311A *May 9, 2013Aug 21, 2013齐鲁制药有限公司Method for preparing antibody-maytansine alkaloid medicine conjugateCN103254311B *May 9, 2013May 13, 2015齐鲁制药有限公司Method for preparing antibody-maytansine alkaloid medicine conjugateCN103717262A *Mar 29, 2012Apr 9, 2014伊缪诺金公司Preparation of maytansinoid antibody conjugates by a one-step processDE19514088A1 *Apr 13, 1995Oct 17, 1996Deutsches KrebsforschKonjugat zur Behandlung von Entz�nduns-, Infektions- und/oder HauterkrankungenEP1229934A2 *Sep 29, 2000Aug 14, 2002Immunogen, Inc.Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsEP1391213A1 *Aug 21, 2002Feb 25, 2004Boehringer Ingelheim International GmbHCompositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agentsEP1649870A2May 4, 2000Apr 26, 2006Genentech, Inc.Treatment of autoimmune diseases with antagonists which bind to B cell surface markersEP1651162A2 *May 20, 2004May 3, 2006Immunogen, Inc.Improved cytotoxic agents comprising new maytansinoidsEP1651162A4 *May 20, 2004Jun 30, 2010Immunogen IncImproved cytotoxic agents comprising new maytansinoidsEP1798240A1Dec 14, 2006Jun 20, 2007Industrial Technology Research InstituteRecombinant triplex scaffold-based polypeptidesEP1806365A1Jan 5, 2006Jul 11, 2007Boehringer Ingelheim International GmbHAntibody molecules specific for fibroblast activation protein and immunoconjugates containing themEP1813614A1Jan 25, 2006Aug 1, 2007Sanofi-AventisCytotoxic agents comprising new tomaymycin derivativesEP1913002A2 *Aug 8, 2006Apr 23, 2008Millennium Pharmaceuticals, Inc.Method of acylating maytansinol with chiral amino acidsEP1992643A2Jun 19, 2002Nov 19, 2008Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP1995321A2Jul 18, 2006Nov 26, 2008Genentech, Inc.Gene disruptions, compositions and methods relating theretoEP2000148A1Jun 19, 2002Dec 10, 2008Genentech, Inc.Compositions and methods for the diagnosis and treatment of prostate cancerEP2000482A1Jun 19, 2002Dec 10, 2008Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2000545A1Jun 19, 2002Dec 10, 2008Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2002714A1Nov 16, 2006Dec 17, 2008Genentech, Inc.Novel gene disruptions, compositions and methods relating theretoEP2011886A2Apr 10, 2003Jan 7, 2009Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2042517A1Sep 26, 2003Apr 1, 2009Xencor, Inc.Optimized FC variants and methods for their generationEP2050335A1Feb 9, 2007Apr 22, 2009Genentech, Inc.Gene disruptions, compositions and methods relating theretoEP2052742A1Jun 14, 2001Apr 29, 2009Biogen Idec Inc.Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combinationEP2062916A2Apr 6, 2004May 27, 2009Genentech, Inc.Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitorEP2065402A1Jan 23, 2008Jun 3, 2009Industrial Technology Research InstitutTrimeric collagen scaffold antibodiesEP2067472A1Dec 30, 2002Jun 10, 2009Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2082645A1Apr 18, 2007Jul 29, 2009Genentech, Inc.Novel gene disruptions, compositions and methods relating theretoEP2112167A2Jun 23, 2000Oct 28, 2009Genentech, Inc.Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodiesEP2143437A1Sep 11, 2002Jan 13, 2010Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2143438A1Sep 11, 2002Jan 13, 2010Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2151244A1Sep 11, 2002Feb 10, 2010Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2153843A1Sep 11, 2002Feb 17, 2010Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorEP2161283A1Nov 16, 2004Mar 10, 2010Genentech, Inc.Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic originEP2186402A1May 18, 2006May 19, 2010Genentech, Inc.Knock-out animal models for novel genes and methods of useEP2230517A1Jan 9, 2006Sep 22, 2010Diadexus, Inc.OVR110 antibody compositions and methods of useEP2238988A1Mar 20, 2003Oct 13, 2010ImmunoGen, Inc.Conjugated prodrugs of cc-1065 analogsEP2241577A1Aug 8, 2008Oct 20, 2010Boehringer Ingelheim International GmbHAnti-CD37 antibodiesEP2263691A1Jul 11, 2003Dec 22, 2010Genentech, Inc.Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)EP2266607A2Sep 29, 2000Dec 29, 2010Immunogen, Inc.Immunoconjugates for treating cancerEP2275448A2Dec 17, 2004Jan 19, 2011Genentech, Inc.Monovalent antibody fragments useful as therapeuticsEP2277542A1May 30, 2002Jan 26, 2011Cornell Research Foundation Inc.Modified antibodies to prostrate-specific membrane antigen and uses thereofEP2277908A2Jun 2, 2004Jan 26, 2011Genentech, Inc.IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereofEP2281577A2May 14, 2004Feb 9, 2011Immunogen, Inc.Drug conjugate compositionEP2283866A2Jun 23, 2000Feb 16, 2011Genentech, Inc.Methods of treatment using anti-ERBB antibody-maytansinoid conjugatesEP2283867A2Jun 23, 2000Feb 16, 2011Genentech, Inc.Methods of treatment using anti-ERBB antibody-maytansinoid conjugatesEP2286844A2May 31, 2005Feb 23, 2011Genentech, Inc.Antibody-drug conjugates and methodsEP2289549A2Sep 29, 2000Mar 2, 2011Immunogen, Inc.Immunoconjugates for treating cancerEP2295073A1Nov 16, 2004Mar 16, 2011Genentech, Inc.Antibody against CD22 for the treatment of tumour of hematopoietic originEP2298805A2Sep 26, 2003Mar 23, 2011Xencor, Inc.Optimized Fc variants and methods for their generationEP2301568A1Nov 16, 2004Mar 30, 2011Genentech, Inc.Antibody against IRTA2 for the treatment of tumour of hematopoietic originEP2311880A2Jan 5, 2006Apr 20, 2011Biogen Idec MA Inc.Cripto binding moleculesEP2311881A2Jan 5, 2006Apr 20, 2011Biogen Idec MA Inc.Cripto binding moleculesEP2322556A1Sep 2, 2005May 18, 2011Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforEP2325208A1Dec 14, 2006May 25, 2011Genentech, Inc.Polyubiquitin antibodiesEP2335725A1Mar 29, 2004Jun 22, 2011Genentech, Inc.High concentration antibody and protein formulationsEP2336170A2Dec 14, 2006Jun 22, 2011Industrial Technology Research InstituteRecombinant triplex scaffold-based polypeptidesEP2338912A2Dec 14, 2006Jun 29, 2011Industrial Technology Research InstituteRecombinant triplex scaffold-base polypeptidesEP2341050A1Jul 14, 2003Jul 6, 2011ImmunoGen, Inc.Cytotoxic agents containing novel potent taxanes and their therapeutic useEP2345671A1Sep 26, 2003Jul 20, 2011Xencor Inc.Optimized fc variants and methods for their generationEP2348024A2Feb 14, 2002Jul 27, 2011ImmunoGen, Inc.Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsEP2361931A1Jul 19, 2005Aug 31, 2011Genentech, Inc.Inhibitors of angiopoietin-like 4 protein, combinations, and their useEP2364996A1Sep 26, 2003Sep 14, 2011Xencor Inc.Optimized FC variants and methods for their generationEP2368911A1Mar 26, 2004Sep 28, 2011Xencor Inc.Optimized Fc variants and methods for their generationEP2371388A2Oct 19, 2005Oct 5, 2011Genentech, Inc.Antibody formulationsEP2371827A1Jan 22, 2007Oct 5, 2011SanofiCytotoxic agents comprising new tomaymycin derivatives and their therapeutic useEP2383297A1Aug 14, 2007Nov 2, 2011Xencor Inc.Optimized antibodies that target CD19EP2384767A1Mar 10, 2006Nov 9, 2011Millennium Pharmaceuticals, Inc.Antibodies that bind OV064 and methods of use thereforEP2386559A1Jan 22, 2007Nov 16, 2011SanofiCytotoxiv agents comprising new tomaymycin derivatives and their therapeutic useEP2386655A2Sep 10, 2007Nov 16, 2011Genentech, Inc.Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic markerEP2389946A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389947A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389948A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389949A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389950A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2389951A1Mar 22, 2007Nov 30, 2011Novartis AGAnti-tumor cell antigen antibody therapeuticsEP2399605A1Feb 21, 2006Dec 28, 2011Genentech, Inc.Extending time to disease progression or survival in cancer patientsEP2399609A1Aug 14, 2006Dec 28, 2011ImmunoGen, Inc.Process for preparing maytansinoid antibody conjugatesEP2402373A2Jan 4, 2007Jan 4, 2012Genentech, Inc.Anti-EphB4 Antibodies and Methods Using SameEP2423332A1Aug 23, 2007Feb 29, 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancerEP2423333A1Aug 23, 2007Feb 29, 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancerEP2436393A1Dec 19, 2002Apr 4, 2012Millennium Pharmaceuticals, Inc.Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses thereforEP2446904A2May 29, 2007May 2, 2012Genentech, Inc.Anti-CD22 antibodies, their immunoconjugates and uses thereofEP2447282A2May 29, 2007May 2, 2012Genentech, Inc.Anti-CD22 Antibodies, their Immunoconjugates and uses thereofEP2447372A2Jul 10, 2006May 2, 2012Biogen Idec MA Inc.Anti alpha v beta 6 antibodies and uses thereofEP2450050A1Nov 20, 2007May 9, 2012Genentech, Inc.IL-17A/F heterodimeric polypeptides and therapeutic uses thereofEP2457586A1Jun 25, 2004May 30, 2012Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofEP2457587A1Jun 25, 2004May 30, 2012Amgen Fremont Inc.Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofEP2458012A1Jul 10, 2006May 30, 2012Biogen Idec MA Inc.Anti alpha v beta 6 antibodies and uses thereofEP2458013A1Jul 10, 2006May 30, 2012Biogen Idec MA Inc.Anti alpha v beta 6 antibodies and uses therofEP2465870A1Nov 7, 2006Jun 20, 2012Genentech, Inc.Binding polypeptides with diversified and consensus VH/VL hypervariable sequencesEP2468304A2Feb 10, 2006Jun 27, 2012ImmunoGen, Inc.Process for preparing stable drug conjugatesEP2468772A2Mar 16, 2007Jun 27, 2012Genentech, Inc.Antibodies to EGFL7 and methods for their useEP2471813A1May 5, 2005Jul 4, 2012Xencor Inc.Optimized Fc variantsEP2474557A2Jul 15, 2008Jul 11, 2012Genentech, Inc.Anti-CD79b antibodies and immunoconjugates and methods of useEP2502937A2Jul 15, 2008Sep 26, 2012Genentech, Inc.Anti-CD 79b Antibodies And Immunoconjugates And Methods Of UseEP2514828A2Dec 12, 2005Oct 24, 2012ImmunoGen, Inc.Methods for the production of ansamitocinsEP2550975A1 *Jul 29, 2011Jan 30, 2013SanofiCombination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximabEP2562187A1Aug 8, 2008Feb 27, 2013Boehringer Ingelheim International GmbHAnti-CD37 antibodiesEP2596803A2Oct 12, 2004May 29, 2013ImmunoGen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesEP2596804A2Oct 12, 2004May 29, 2013ImmunoGen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesEP2612682A2Oct 12, 2004Jul 10, 2013ImmunoGen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesEP2614839A2Jan 22, 2007Jul 17, 2013Genentech, Inc.Method for using BOC/CDO to modulate hedgehog signalingEP2623516A2Nov 30, 2006Aug 7, 2013Genentech, Inc.Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22REP2633864A1Jul 23, 2009Sep 4, 2013The Regents of the University of ColoradoClip inhibitors and methods of modulating immune functionEP2638907A2Mar 10, 2009Sep 18, 2013Genentech, Inc.Combinations of an anti-HER2 antibody-drug conjugate and lapatinibEP2641618A2Jul 15, 2008Sep 25, 2013Genentech, Inc.Humanized anti-CD79B antibodies and immunoconjugates and methods of useEP2644194A2Mar 10, 2009Oct 2, 2013Genentech, Inc.Combinations of an anti-HER2 antibody-drug conjugate and docetaxelEP2644204A2Mar 10, 2009Oct 2, 2013Genentech, Inc.Combinations of an anti-HER2 antibody-drug conjugate and pertuzumabEP2644205A1Apr 11, 2008Oct 2, 2013The Brigham and Women's Hospital, Inc.Targeting ABCB5 for cancer therapyEP2657253A2Jan 14, 2009Oct 30, 2013Genentech, Inc.Anti-CD79b antibodies and immunoconjugates and methods of useEP2662096A1Aug 14, 2006Nov 13, 2013ImmunoGen, Inc.Process for preparing maytansinoid antibody conjugatesEP2679600A1Mar 24, 2010Jan 1, 2014Genentech, Inc.Anti-FGFR3 antibodies and methods using sameEP2708557A1May 30, 2008Mar 19, 2014Xencor, Inc.Method and compositions for inhibiting CD32B expressing cellsEP2711018A1Jun 21, 2010Mar 26, 2014MedImmune, LLCEngineered Fc regions for site-specific conjugationEP2772260A2Sep 4, 2006Sep 3, 2014Alchemia Oncology Pty LimitedTherapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatmentEP2784084A1Jun 2, 2004Oct 1, 2014Genentech, Inc.IL-17 A/F heterologous polypeptides and therapeutics uses thereofEP2801584A1Dec 23, 2008Nov 12, 2014Biotest AGAgents targeting CD138 and uses thereofEP2803367A1Jun 23, 2000Nov 19, 2014ImmunoGen, Inc.Methods of treatment using anti-ERBB antibody-maytansinoid conjugatesEP2845866A1Oct 26, 2007Mar 11, 2015Genentech, Inc.Antibodies and immunoconjugates and uses thereforEP2845912A1Sep 10, 2007Mar 11, 2015Genentech, Inc.Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic markerEP2851372A1Dec 1, 2008Mar 25, 2015Genentech, Inc.Anti-VEGF antibodiesEP2857516A1Mar 20, 2001Apr 8, 2015Genentech, Inc.Multivalent antibodies and uses thereforEP2862871A1Apr 14, 2009Apr 22, 2015The General Hospital CorporationPlectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinomaEP2894167A1Jun 17, 2010Jul 15, 2015AbbVie Biotherapeutics Inc.Anti-VEGF Antibodies and their usesEP2896404A2Jun 4, 2010Jul 22, 2015Novartis AGMethods for identification of sites for IgG conjugationEP2899541A1Feb 29, 2008Jul 29, 2015Genentech, Inc.Predicting response to a HER dimerisation inhbitor based on low HER3 expressionEP2918602A1Apr 16, 2010Sep 16, 2015AbbVie Biotherapeutics Inc.Anti-TNF-alpha antibodies and their usesEP2926830A2Aug 31, 2011Oct 7, 2015Theraclone Sciences, Inc.Human immunodeficiency virus (HIV)-neutralizing antibodiesEP2946786A1Mar 8, 2007Nov 25, 2015Wake Forest University Health SciencesSoluble monomeric Ephrin A1EP2962697A1Nov 27, 2007Jan 6, 2016diaDexus, Inc.Ovr110 antibody compositions and methods of useEP2977063A1Jun 23, 2000Jan 27, 2016Genentech, Inc.Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesEP2982380A1Mar 1, 2011Feb 10, 2016MacroGenics, Inc.Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereofEP2998405A1May 13, 2010Mar 23, 2016Genzyme CorporationAnti-human cd52 immunoglobulinsEP3002297A2Nov 29, 2010Apr 6, 2016F. Hoffmann-La Roche AGAntibodies for treating and diagnosing tumors expressing slc34a2 (tat211)EP3006466A2Nov 30, 2006Apr 13, 2016Genentech, Inc.Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22rEP3011971A1Jun 25, 2004Apr 27, 2016Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofEP3029066A2Jul 29, 2011Jun 8, 2016Xencor, Inc.Antibodies with modified isoelectric pointsEP3031810A1May 20, 2004Jun 15, 2016ImmunoGen, Inc.Improved cytotoxic agents comprising new maytansinoidsEP3037105A1Jun 25, 2004Jun 29, 2016Amgen Fremont Inc.Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofEP3053600A1Feb 15, 2012Aug 10, 2016ImmunoGen, Inc.Cytotoxic benzodiazepine derivativesWO2001077342A1Mar 20, 2001Oct 18, 2001Genentech, Inc.Multivalent antibodies and uses thereforWO2002016368A1 *Apr 26, 2001Feb 28, 2002Immunogen, Inc.Process for the preparation and purification of thiol-containing maytansinoidsWO2002022554A1 *Sep 12, 2001Mar 21, 2002Smithkline Beecham CorporationProcess and intermediatesWO2002094325A2 *May 16, 2002Nov 28, 2002Boehringer Ingelheim International GmbhCytotoxic cd44 antibody immunoconjugatesWO2002094325A3 *May 16, 2002Apr 17, 2003Guenther AdolfCytotoxic cd44 antibody immunoconjugatesWO2002098883A1Feb 14, 2002Dec 12, 2002Immunogen, Inc.Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsWO2003068144A2 *Sep 10, 2002Aug 21, 2003Immunogen, Inc.Cytotoxic agentsWO2003068144A3 *Sep 10, 2002Aug 5, 2004Immunogen IncCytotoxic agentsWO2004018000A2 *Aug 19, 2003Mar 4, 2004Boehringer Ingelheim International GmbhCompositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agentsWO2004018000A3 *Aug 19, 2003Sep 2, 2004Guenther AdolfCompositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agentsWO2004098535A2Mar 3, 2004Nov 18, 2004Millennium Pharmaceuticals, Inc.Modified antibodies to prostate-specific membrane antigen and uses thereofWO2004101756A2May 10, 2004Nov 25, 2004Diadexus, Inc.Ovr110 antibody compositions and methods of useWO2005017529A1Jun 24, 2004Feb 24, 2005Genentech, Inc.Assay for human anti cd20 antibodies and uses thereforWO2005037992A2Oct 12, 2004Apr 28, 2005Immunogen, Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesWO2005099756A2Apr 7, 2005Oct 27, 2005Agus David BErbB ANTAGONISTS FOR PAIN THERAPYWO2006014928A1Jul 25, 2005Feb 9, 2006Genentech, Inc.Methods and compositions for modulating hepatocyte growth factor activationWO2006026759A2Sep 2, 2005Mar 9, 2006Genentech, Inc.Humanized anti-beta7 antagonists and uses thereforWO2006033700A2Jul 15, 2005Mar 30, 2006Genentech, Inc.Her2 antibody compositionWO2006062779A2Nov 30, 2005Jun 15, 2006Centocor, Inc.Anti-integrin immunoconjugates, methods and usesWO2006074418A2Jan 9, 2006Jul 13, 2006Diadexus, Inc.Ovr110 antibody compositions and methods of useWO2006078368A1 *Dec 12, 2005Jul 27, 2006Immunogen, Inc.Methods for the production of ansamitocinsWO2006091693A2Feb 21, 2006Aug 31, 2006Genentech, Inc.Extending time to disease progression or survival in cancer patients using a her dimerization inhibitorWO2006113623A2 *Apr 14, 2006Oct 26, 2006Immunogen, Inc.Elimination of heterogeneous or mixed cell population in tumorsWO2006113623A3 *Apr 14, 2006Sep 12, 2008Ravi V J ChariElimination of heterogeneous or mixed cell population in tumorsWO2007008712A2Jul 10, 2006Jan 18, 2007Biogen Idec Ma Inc.Anti-alpha v beta 6 antibodies and uses thereofWO2007076465A2 *Dec 22, 2006Jul 5, 2007Diadexus, Inc.Cln248 antibody compositions and methods of useWO2007127506A2Jan 19, 2007Nov 8, 2007Genentech, Inc.Anti-ephrinb2 antibodies and methods using sameWO2007144709A2May 23, 2007Dec 21, 2007Sanofi-AventisLeptomycin derivativesWO2008033782A2Sep 10, 2007Mar 20, 2008Genentech, Inc.Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic markerWO2008150525A1Jun 3, 2008Dec 11, 2008Genentech, Inc.Anti-notch1 nrr antibodies and methods using sameWO2009028158A1Aug 21, 2008Mar 5, 2009Oncotherapy Science, Inc.Dkk1 oncogene as therapeutic target for cancer and a diagnosing markerWO2009028521A1Aug 20, 2008Mar 5, 2009Oncotherapy Science, Inc.Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosisWO2009046123A2Oct 1, 2008Apr 9, 2009Genentech, Inc.Nlrr-1 antagonists and uses thereofWO2010039832A1Sep 30, 2009Apr 8, 2010Genentech, Inc.Anti-notch2 antibodies and methods of useWO2010060920A1Nov 25, 2009Jun 3, 2010INSERM (Institut National de la Sant� et de la Recherche M�dicale)Cxcl4l1 as a biomarker of pancreatic cancerWO2010068437A1Nov 24, 2009Jun 17, 2010Genentech, Inc.Isoform specific anti-her4 antibodiesWO2010080528A1Dec 17, 2009Jul 15, 2010Genentech, Inc.Hepatitis c virus combination therapyWO2010091150A1Feb 4, 2010Aug 12, 2010Immunogen, Inc.Novel benzodiazepine derivativesWO2010096486A1Feb 17, 2010Aug 26, 2010Cornell Research Foundation, Inc.Methods and kits for diagnosis of cancer and prediction of therapeutic valueWO2010108127A1Mar 19, 2010Sep 23, 2010Genentech, Inc.Bispecific anti-her antibodiesWO2010111254A1Mar 23, 2010Sep 30, 2010Genentech, Inc.Novel anti-alpha5beta1 antibodies and uses thereofWO2010111367A1Mar 24, 2010Sep 30, 2010Genentech, Inc.Anti-fgfr3 antibodies and methods using sameWO2010120561A1Mar 31, 2010Oct 21, 2010Genentech, Inc.Anti-fcrh5 antibodies and immunoconjugates and methods of useWO2010126551A1Oct 6, 2009Nov 4, 2010Immunogen, Inc.Potent conjugates and hydrophilic linkersWO2010141902A2Jun 4, 2010Dec 9, 2010Novartis AgMETHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATIONWO2010148223A2Jun 17, 2010Dec 23, 2010Facet Biotech CorporationAnti-vegf antibodies and their usesWO2011001052A1May 20, 2010Jan 6, 2011Sanofi-AventisNovel conjugates, preparation thereof, and therapeutic use thereofWO2011014750A1Jul 30, 2010Feb 3, 2011Genentech, Inc.Inhibition of tumor metastasis using bv8- or g-csf-antagonistsWO2011028950A1Sep 2, 2010Mar 10, 2011Genentech, Inc.Mutant smoothened and methods of using the sameWO2011032296A1Sep 21, 2010Mar 24, 2011Mount Sinai HospitalMethods and compositions for the diagnosis and treatment of thyroid cancerWO2011039721A1Sep 30, 2010Apr 7, 2011Sanofi-AventisNew maytansinoids and the use of said maytansinoids to prepare conjugates with an antibodyWO2011039724A1Sep 30, 2010Apr 7, 2011Sanofi-AventisAntibodies that specifically bind to the epha2 receptorWO2011041319A2Sep 28, 2010Apr 7, 2011Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereofWO2011049868A1Oct 18, 2010Apr 28, 2011Genentech, Inc.Modulators of hepatocyte growth factor activatorWO2011050188A1Oct 21, 2010Apr 28, 2011Genentech, Inc.Anti-hepsin antibodies and methods using sameWO2011050194A1Oct 21, 2010Apr 28, 2011Genentech, Inc.Methods and compositions for modulating hepsin activation of macrophage-stimulating proteinWO2011057120A1Nov 5, 2010May 12, 2011Genentech, Inc.Methods and composition for secretion of heterologous polypeptidesWO2011059762A1Oct 28, 2010May 19, 2011Abbott Biotherapeutics Corp.Anti-egfr antibodies and their usesWO2011066503A2Nov 29, 2010Jun 3, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2011069074A2Dec 3, 2010Jun 9, 2011Genentech, Inc.Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1WO2011071577A1Sep 15, 2010Jun 16, 2011Genentech, Inc.Anti-vegf-c antibodies and methods using sameWO2011076922A1Dec 23, 2010Jun 30, 2011Synimmune GmbhAnti-flt3 antibodies and methods of using the sameWO2011079185A1Dec 22, 2010Jun 30, 2011Genentech, Inc.Anti-bv8 antibodies and uses thereofWO2011080796A1Dec 28, 2009Jul 7, 2011Oncotherapy Science, Inc.Anti-cdh3 antibodies and uses thereofWO2011084496A1Dec 15, 2010Jul 14, 2011Abbott Biotherapeutics Corp.Anti-her2 antibodies and their usesWO2011089211A1Jan 21, 2011Jul 28, 2011Synimmune GmbhAnti-cd133 antibodies and methods of using the sameWO2011100403A1Feb 10, 2011Aug 18, 2011Immunogen, IncCd20 antibodies and uses thereofWO2011103242A1Feb 17, 2011Aug 25, 2011Genentech, Inc.Neuregulin antagonists and use thereof in treating cancerWO2011106297A2Feb 22, 2011Sep 1, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2011107553A1Mar 3, 2011Sep 9, 2011F. Hoffmann-La Roche AgAntibodies against human csf-1r and uses thereofWO2011109400A2Mar 1, 2011Sep 9, 2011Macrogenics,Inc.Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereofWO2011113019A2Mar 11, 2011Sep 15, 2011Abbott Biotherapeutics Corp.Ctla4 proteins and their usesWO2011119661A1Mar 23, 2011Sep 29, 2011Genentech, Inc.Anti-lrp6 antibodiesWO2011131407A1Mar 3, 2011Oct 27, 2011F. Hoffmann-La Roche AgAntibodies against human csf-1r and uses thereofWO2011133886A2Apr 22, 2011Oct 27, 2011Genentech, Inc.Production of heteromultimeric proteinsWO2011137513A1May 4, 2011Nov 10, 2011Paul WalfishMethod for the diagnosis of epithelial cancers by the detection of epicd polypeptideWO2011139985A1May 2, 2011Nov 10, 2011Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumorWO2011146568A1May 18, 2011Nov 24, 2011Genentech, Inc.Predicting response to a her inhibitorWO2011150110A1May 25, 2011Dec 1, 2011Genentech, Inc.Methods of purifying polypeptidesWO2011153346A1Jun 2, 2011Dec 8, 2011Genentech, Inc.Immuno-pet imaging of antibodies and immunoconjugates and uses thereforWO2011156328A1Jun 7, 2011Dec 15, 2011Genentech, Inc.Cysteine engineered antibodies and conjugatesWO2011161119A1Jun 21, 2011Dec 29, 2011F. Hoffmann-La Roche AgAntibodies against insulin-like growth factor i receptor and uses thereofWO2011161189A1Jun 22, 2011Dec 29, 2011F. Hoffmann-La Roche AgAnti-hepsin antibodies and methods of useWO2012010582A1Jul 19, 2011Jan 26, 2012Roche Glycart AgAnti-cxcr5 antibodies and methods of useWO2012014147A1Jul 25, 2011Feb 2, 2012SanofiAnticancer derivatives, preparation thereof and therapeutic use thereofWO2012016227A2Jul 29, 2011Feb 2, 2012Xencor, Inc.Antibodies with modified isoelectric pointsWO2012018771A1Aug 2, 2011Feb 9, 2012Genentech, Inc.Chronic lymphocytic leukemia (cll) biomarkersWO2012019024A2Aug 4, 2011Feb 9, 2012Immunogen, Inc.Her3-binding molecules and immunoconjugates thereofWO2012020006A2Aug 9, 2011Feb 16, 2012Roche Glycart AgAnti-fap antibodies and methods of useWO2012020038A1Aug 10, 2011Feb 16, 2012Roche Glycart AgAnti-tenascin-c a2 antibodies and methods of useWO2012021773A1Aug 12, 2011Feb 16, 2012Genentech, Inc.Antibodies to il-1beta and il-18, for treatment of diseaseWO2012028899A1Sep 2, 2010Mar 8, 2012Inserm ( Institut National De La Sante Et De La Recherche Medicale)Methods for the treatment and the diagnosis of cancerWO2012031027A1Aug 31, 2011Mar 8, 2012Genentech, Inc.Biomarkers and methods of treatmentWO2012045085A1Oct 3, 2011Apr 5, 2012Oxford Biotherapeutics Ltd.Anti-rori antibodiesWO2012047968A2Oct 5, 2011Apr 12, 2012Genentech, Inc.Mutant smoothened and methods of using the sameWO2012057328A1Oct 28, 2011May 3, 2012Perseus Proteomics Inc.Anti-cdh3 antibody having high internalizing capabilityWO2012064836A1Nov 9, 2011May 18, 2012Genentech, Inc.Methods and compositions for neural disease immunotherapyWO2012074757A1Nov 16, 2011Jun 7, 2012Genentech, Inc.Alaninyl maytansinol antibody conjugatesWO2012075037A1Nov 29, 2011Jun 7, 2012Genentech, Inc.Low affinity blood brain barrier receptor antibodies and uses thereforWO2012078771A1Dec 7, 2011Jun 14, 2012Genentech, Inc.Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1WO2012085111A1Dec 21, 2011Jun 28, 2012F. Hoffmann-La Roche AgPolypeptide-polynucleotide-complex and its use in targeted effector moiety deliveryWO2012087962A2Dec 19, 2011Jun 28, 2012Genentech, Inc.Anti-mesothelin antibodies and immunoconjugatesWO2012088313A1Dec 21, 2011Jun 28, 2012Genentech, Inc.Anti-pcsk9 antibodies and methods of useWO2012092616A1Dec 30, 2011Jul 5, 2012Takeda Pharmaceutical Company LimitedConjugated anti-cd38 antibodiesWO2012106587A1Feb 3, 2012Aug 9, 2012Genentech, Inc.Fc VARIANTS AND METHODS FOR THEIR PRODUCTIONWO2012109624A2Feb 10, 2012Aug 16, 2012Zyngenia, Inc.Monovalent and multivalent multispecific complexes and uses thereofWO2012112687A1Feb 15, 2012Aug 23, 2012Immunogen, Inc.Methods of preparation of conjugatesWO2012112708A1Feb 15, 2012Aug 23, 2012Immunogen, Inc.Cytotoxic benzodiazepine derivatives and methods of preparationWO2012125614A1Mar 13, 2012Sep 20, 2012Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenzaWO2012128868A1Feb 15, 2012Sep 27, 2012Immunogen, Inc.Cytotoxic benzodiazepine derivativesWO2012130831A1Mar 27, 2012Oct 4, 2012Roche Glycart AgAntibody fc variantsWO2012135360A1Mar 28, 2012Oct 4, 2012Ludwig Institute For Cancer Research Ltd.Binding proteins specific for egfr expressed on tumor and uses thereofWO2012135517A2Mar 29, 2012Oct 4, 2012Immunogen, Inc.Preparation of maytansinoid antibody conjugates by a one-step processWO2012135517A3 *Mar 29, 2012Feb 21, 2013Immunogen, Inc.Preparation of maytansinoid antibody conjugates by a one-step processWO2012135522A2Mar 29, 2012Oct 4, 2012Immunogen, Inc.Process for manufacturing conjugates of improved homogeneityWO2012138975A1Apr 6, 2012Oct 11, 2012Genentech, Inc.Anti-fgfr4 antibodies and methods of useWO2012143379A1Apr 18, 2012Oct 26, 2012Roche Glycart AgMethod and constructs for the ph dependent passage of the blood-brain-barrierWO2012154809A1May 9, 2012Nov 15, 2012University Of Virginia Patent FoundationCompositions and methods for treating cancerWO2012158704A1May 15, 2012Nov 22, 2012Genentech, Inc.Fgfr1 agonists and methods of useWO2012171020A1Jun 11, 2012Dec 13, 2012Mersana Therapeutics, Inc.Protein-polymer-drug conjugatesWO2012177837A2Jun 21, 2012Dec 27, 2012Immunogen, Inc.Novel maytansinoid derivatives with peptide linker and conjugates thereofWO2012177837A3 *Jun 21, 2012Jul 11, 2013Immunogen, Inc.Novel maytansinoid derivatives with peptide linker and conjugates thereofWO2013003680A1Jun 29, 2012Jan 3, 2013Genentech, Inc.Anti-c-met antibody formulationsWO2013006706A1Jul 5, 2012Jan 10, 2013Bioasis Technologies Inc.P97-antibody conjugates and methods of useWO2013012733A1Jul 13, 2012Jan 24, 2013Biogen Idec Ma Inc.Heterodimeric fc regions, binding molecules comprising same, and methods relating theretoWO2013015821A1Sep 19, 2011Jan 31, 2013The Research Foundation Of State University Of New YorkAntibodies to the b12-transcobalamin receptorWO2013017540A1 *Jul 27, 2012Feb 7, 2013SanofiCombination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an anti-cd19 maytansinoid immunoconjugate and rituximabWO2013022855A1Aug 6, 2012Feb 14, 2013Xencor, Inc.Antibodies with modified isoelectric points and immunofilteringWO2013025853A1Aug 16, 2012Feb 21, 2013Genentech, Inc.Neuregulin antibodies and uses thereofWO2013025944A1Aug 16, 2012Feb 21, 2013Genentech, Inc.Inhibition of angiogenesis in refractory tumorsWO2013026832A1Aug 21, 2012Feb 28, 2013Roche Glycart AgAnti-mcsp antibodiesWO2013026835A1Aug 21, 2012Feb 28, 2013Roche Glycart AgFc-free antibodies comprising two fab fragments and methods of useWO2013026839A1Aug 21, 2012Feb 28, 2013Roche Glycart AgBispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of useWO2013033069A1Aug 28, 2012Mar 7, 2013Theraclone Sciences, Inc.Human rhinovirus (hrv) antibodiesWO2013033380A1Aug 30, 2012Mar 7, 2013Genentech, Inc.Diagnostic markersWO2013040433A1Sep 14, 2012Mar 21, 2013Genentech, Inc.Methods of promoting differentiationWO2013041462A1Sep 14, 2012Mar 28, 2013Roche Glycart AgBispecific anti-egfr/anti igf-1r antibodiesWO2013043715A1Sep 19, 2012Mar 28, 2013Genentech, Inc.Combination treatments comprising c-met antagonists and b-raf antagonistsWO2013043933A2Sep 20, 2012Mar 28, 2013Amgen Inc.Cd27l antigen binding proteinsWO2013052155A1Apr 6, 2012Apr 11, 2013Genentech, Inc.Methods of treating liver conditions using notch2 antagonistsWO2013055809A1Oct 10, 2012Apr 18, 2013Xencor, Inc.A method for purifying antibodiesWO2013055998A1Oct 12, 2012Apr 18, 2013Genentech, Inc.ANTI-HtrA1 ANTIBODIES AND METHODS OF USEWO2013056054A2Oct 12, 2012Apr 18, 2013Genentech, IncPeptide inhibitors of bace1WO2013056148A2Oct 12, 2012Apr 18, 2013Genentech, Inc.Methods of using scd1 antagonistsWO2013067301A1Nov 2, 2012May 10, 2013Genentech, Inc.Overload and elute chromatographyWO2013075048A1Nov 16, 2012May 23, 2013Amgen Inc.Methods of treating epidermal growth factor deletion mutant viii related disordersWO2013075066A2Nov 18, 2012May 23, 2013Eleven Biotherapeutics, Inc.Proteins with improved half-life and other propertiesWO2013078170A1Nov 20, 2012May 30, 2013Genentech, Inc.Purification of anti-c-met antibodiesWO2013078377A1Nov 21, 2012May 30, 2013Igenica, Inc.Anti-cd98 antibodies and methods of use thereofWO2013083817A1Dec 7, 2012Jun 13, 2013Biotest AgUses of immunoconjugates targeting cd138WO2013093809A1Dec 19, 2012Jun 27, 2013Pfizer Inc.Engineered antibody constant regions for site-specific conjugation and methods and uses thereforWO2013096812A1Dec 21, 2012Jun 27, 2013Genentech, Inc.Articles of manufacture and methods for co-administration of antibodiesWO2013101771A2Dec 21, 2012Jul 4, 2013Genentech, Inc.Compositions and method for treating autoimmune diseasesWO2013106489A1Jan 9, 2013Jul 18, 2013The Scripps Research InstituteHumanized antibodies with ultralong cdr3sWO2013109819A1Jan 18, 2013Jul 25, 2013Genentech, Inc.Anti-lrp5 antibodies and methods of useWO2013109856A2Jan 18, 2013Jul 25, 2013Genentech, Inc.Methods of using fgf19 modulatorsWO2013109994A1Jan 18, 2013Jul 25, 2013Sea Lane Biotechnologies, LlcSurrobody cojugatesWO2013116287A1Jan 30, 2013Aug 8, 2013Genentech, Inc.Anti-ig-e m1' antibodies and methods using sameWO2013120056A1Feb 11, 2013Aug 15, 2013Genentech, Inc.R-spondin translocations and methods using the sameWO2013120929A1Feb 14, 2013Aug 22, 2013F. Hoffmann-La Roche AgFc-receptor based affinity chromatographyWO2013130093A1Mar 2, 2012Sep 6, 2013Genentech, Inc.Biomarkers for treatment with anti-tubulin chemotherapeutic compoundsWO2013134743A1Mar 8, 2013Sep 12, 2013Halozyme, Inc.Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereofWO2013149159A1Mar 29, 2013Oct 3, 2013Genentech, Inc.Anti-lgr5 antibodies and immunoconjugatesWO2013150623A1Apr 4, 2012Oct 10, 2013Perseus Proteomics Inc.Conjugate of anti-cdh3 (p-cadherin) antibody and drugWO2013151736A2Mar 15, 2013Oct 10, 2013modeRNA TherapeuticsIn vivo production of proteinsWO2013160396A1Apr 25, 2013Oct 31, 2013Boehringer Ingelheim International GmbhCombination of cd37 antibodies with bendamustineWO2013165940A1Apr 30, 2013Nov 7, 2013Genentech, Inc.Anti-pmel17 antibodies and immunoconjugatesWO2013170191A1May 10, 2013Nov 14, 2013Genentech, Inc.Methods of using antagonists of nad biosynthesis from nicotinamideWO2013171287A1May 15, 2013Nov 21, 2013Boehringer Ingelheim International GmbhCombination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)WO2013171289A1May 15, 2013Nov 21, 2013Boehringer Ingelheim International GmbhCombination of cd37 antibodies with further agentsWO2013177062A2May 20, 2013Nov 28, 2013Genentech, Inc.Methods for improving safety of blood-brain barrier transportWO2013182668A1Jun 7, 2013Dec 12, 2013F. Hoffmann-La Roche AgMutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerWO2014001326A1Jun 25, 2013Jan 3, 2014F. Hoffmann-La Roche AgMethod for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereofWO2014006118A1Jul 4, 2013Jan 9, 2014F. Hoffmann-La Roche AgAnti-theophylline antibodies and methods of useWO2014006123A1Jul 4, 2013Jan 9, 2014F. Hoffmann-La Roche AgAnti-biotin antibodies and methods of useWO2014006124A1Jul 4, 2013Jan 9, 2014F. Hoffmann-La Roche AgCovalently linked antigen-antibody conjugatesWO2014011518A1Jul 8, 2013Jan 16, 2014Genentech, Inc.Immunoconjugates comprising anti-cd22 antibodiesWO2014011519A1Jul 8, 2013Jan 16, 2014Genentech, Inc.Immunoconjugates comprising anti-cd79b antibodiesWO2014011520A1Jul 8, 2013Jan 16, 2014Genentech, Inc.Immunoconjugates comprising anti-cd22 antibodiesWO2014011521A1Jul 8, 2013Jan 16, 2014Genentech, Inc.Immunoconjugates comprising anti - cd79b antibodiesWO2014022515A1Jul 31, 2013Feb 6, 2014Bioasis Technologies, Inc.Dephosphorylated lysosomal storage disease proteins and methods of use thereofWO2014033074A1Aug 26, 2013Mar 6, 2014F. Hoffmann-La Roche AgBlood brain barrier shuttleWO2014047222A2Sep 18, 2013Mar 27, 2014Abbvie Biotherapeutics Inc.Methods for identifying antibodies with reduced immunogenicityWO2014056783A1Oct 3, 2013Apr 17, 2014Roche Glycart AgFc-free antibodies comprising two fab-fragments and methods of useWO2014068079A1Nov 1, 2013May 8, 2014Max-Delbr�ck-Centrum f�r Molekulare MedizinAn antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseasesWO2014072306A1Nov 6, 2013May 15, 2014F. Hoffmann-La Roche AgHer3 antigen binding proteins binding to the beta-hairpin of her3WO2014078268A2Nov 12, 2013May 22, 2014Genentech, Inc.Anti-hemagglutinin antibodies and methods of useWO2014079886A1Nov 20, 2013May 30, 2014SanofiAnti-ceacam5 antibodies and uses thereofWO2014081507A1Oct 2, 2013May 30, 2014Moderna Therapeutics, Inc.Terminally modified rnaWO2014085654A1Nov 27, 2013Jun 5, 2014Abbvie Biotherapeutics Inc.Anti-vegf antibodies and their usesWO2014089335A2Dec 5, 2013Jun 12, 2014Amgen Inc.Bcma antigen binding proteinsWO2014093379A1Dec 10, 2013Jun 19, 2014Mersana Therapeutics, Inc.Auristatin compounds and conjugates thereofWO2014093394A1Dec 10, 2013Jun 19, 2014Mersana Therapeutics, Inc.Protein-polymer-drug conjugatesWO2014093640A1Dec 12, 2013Jun 19, 2014Mersana Therapeutics,Inc.Hydroxy-polmer-drug-protein conjugatesWO2014094354A1 *Nov 29, 2013Jun 26, 2014Bio-Thera Solutions, Ltd.Preparation of maytansinoid estersWO2014107739A1Jan 7, 2014Jul 10, 2014Eleven Biotherapeutics, Inc.Antibodies against pcsk9WO2014113510A1Jan 15, 2014Jul 24, 2014Xencor, Inc.Rapid clearance of antigen complexes using novel antibodiesWO2014114207A1Jan 17, 2014Jul 31, 2014Newbio Therapeutics, Inc.Tridentate connexon and use thereofWO2014114801A1Jan 27, 2014Jul 31, 2014Amgen Inc.Antibodies targeting cdh19 for melanomaWO2014126198A1Feb 14, 2014Aug 21, 2014Perseus Proteomics Inc.Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of sameWO2014131715A1Feb 24, 2014Sep 4, 2014Roche Glycart AgAnti-mcsp antibodiesWO2014138364A2Mar 6, 2014Sep 12, 2014Genentech, Inc.Methods of treating and preventing cancer drug resistanceWO2014143739A2Mar 14, 2014Sep 18, 2014Biogen Idec Ma Inc.Anti-alpha v beta 6 antibodies and uses thereofWO2014144466A1Mar 14, 2014Sep 18, 2014Biogen Idec Ma Inc.Anti-alpha v beta 6 antibodies and uses thereofWO2014144865A2Mar 14, 2014Sep 18, 2014Genentech, Inc.Anti-crth2 antibodies and methods of useWO2014144935A2Mar 14, 2014Sep 18, 2014Abbvie Biotherapeutics Inc.Anti-cd25 antibodies and their usesWO2014144960A2Mar 14, 2014Sep 18, 2014Abbvie Biotherapeutics Inc.Fc variantsWO2014145000A2Mar 14, 2014Sep 18, 2014Abbvie Biotherapeutics Inc.Anti-cd25 antibodies and their usesWO2014145090A1Mar 14, 2014Sep 18, 2014Regeneron Pharmaceuticals, Inc.Biologically active molecules, conjugates thereof, and therapeutic usesWO2014145806A2Mar 17, 2014Sep 18, 2014Xencor, Inc.Heterodimeric proteinsWO2014150877A2Mar 12, 2014Sep 25, 2014Ac Immune S.A.Anti-tau antibodies and methods of useWO2014151006A2Mar 12, 2014Sep 25, 2014Genentech, Inc.Biomarkers and methods of treating pd-1 and pd-l1 related conditionsWO2014151644A2Mar 13, 2014Sep 25, 2014Genzyme CorporationAnti-cd52 antibodiesWO2014151866A1Mar 13, 2014Sep 25, 2014Genentech, Inc.Compositions and methods for diagnosis and treatment of hepatic cancersWO2014152540A1Mar 14, 2014Sep 25, 2014Moderna Therapeutics, Inc.Compositions and methods of altering cholesterol levelsWO2014153030A2Mar 14, 2014Sep 25, 2014Genentech, Inc.Methods of treating cancer and preventing cancer drug resistanceWO2014159813A1Mar 13, 2014Oct 2, 2014Moderna Therapeutics, Inc.Long-lived polynucleotide moleculesWO2014159835A1Mar 13, 2014Oct 2, 2014Genentech, Inc.Anti-b7-h4 antibodies and immunoconjugatesWO2014160160A2Mar 13, 2014Oct 2, 2014Novartis AgAntibody drug conjugatesWO2014160438A1Mar 13, 2014Oct 2, 2014Bioasis Technologies Inc.Fragments of p97 and uses thereofWO2014179657A1May 2, 2014Nov 6, 2014Eleven Biotherapeutics, Inc.Albumin variants binding to fcrnWO2015010100A2Jul 18, 2014Jan 22, 2015Fabrus, Inc.Humanized antibodies with ultralong complementarity determining regionsWO2015017146A2Jul 18, 2014Feb 5, 2015Fabrus, Inc.Antibodies with ultralong complementarity determining regionsWO2015017552A1Jul 30, 2014Feb 5, 2015Agensys, Inc.Antibody drug conjugates (adc) that bind to cd37 proteinsWO2015023596A1Aug 11, 2014Feb 19, 2015Genentech, Inc.Compositions and method for treating complement-associated conditionsWO2015031673A2Aug 28, 2014Mar 5, 2015Bioasis Technologies Inc.Cns-targeted conjugates having modified fc regions and methods of use thereofWO2015034925A1Sep 3, 2014Mar 12, 2015Moderna Therapeutics, Inc.Circular polynucleotidesWO2015034928A1Sep 3, 2014Mar 12, 2015Moderna Therapeutics, Inc.Chimeric polynucleotidesWO2015035044A2Sep 4, 2014Mar 12, 2015Abbvie Biotherapeutics Inc.Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITYWO2015038984A2Sep 12, 2014Mar 19, 2015Halozyme, Inc.Modified anti-epidermal growth factor receptor antibodies and methods of use thereofWO2015042108A1Sep 17, 2014Mar 26, 2015Genentech, Inc.Methods of using anti-lgr5 antibodiesWO2015051214A1Oct 3, 2014Apr 9, 2015Moderna Therapeutics, Inc.Polynucleotides encoding low density lipoprotein receptorWO2015052537A1Oct 10, 2014Apr 16, 2015Oxford Biotherapeutics LtdConjugated antibodies against ly75 for the treatment of cancerWO2015054659A1Oct 10, 2014Apr 16, 2015Mersana Therapeutics, Inc.Protein-polymer-drug conjugatesWO2015054669A1Oct 10, 2014Apr 16, 2015Asana Biosciences, LlcProtein-polymer-drug conjugatesWO2015058132A2Oct 17, 2014Apr 23, 2015Genentech, Inc.Anti-rspo antibodies and methods of useWO2015069922A2Nov 6, 2014May 14, 2015The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAlk antibodies, conjugates, and chimeric antigen receptors, and their useWO2015089344A1Dec 12, 2014Jun 18, 2015Genentech, Inc.Anti-cd33 antibodies and immunoconjugatesWO2015095227A2Dec 16, 2014Jun 25, 2015Genentech, Inc.Peptidomimetic compounds and antibody-drug conjugates thereofWO2015101586A1Dec 29, 2014Jul 9, 2015F. Hoffmann-La Roche AgBispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttlesWO2015101587A1Dec 29, 2014Jul 9, 2015F. Hoffmann-La Roche AgCovalently linked helicar-anti-helicar antibody conjugates and uses thereofWO2015101588A1Dec 29, 2014Jul 9, 2015F. Hoffmann-La Roche AgMonovalent blood brain barrier shuttle modulesWO2015101589A1Dec 29, 2014Jul 9, 2015F. Hoffmann-La Roche AgCovalently linked polypeptide toxin-antibody conjugatesWO2015112909A1Jan 23, 2015Jul 30, 2015Genentech, Inc.Methods of using anti-steap1 antibodies and immunoconjugatesWO2015120075A2Feb 4, 2015Aug 13, 2015Genentech, Inc.Mutant smoothened and methods of using the sameWO2015127405A2Feb 23, 2015Aug 27, 2015Genentech, Inc.Anti-il-13/il-17 bispecific antibodies and uses thereofWO2015138460A1Mar 10, 2015Sep 17, 2015Regeneron Pharmaceuticals, Inc.Anti-egfrviii antibodies and uses thereofWO2015138920A1Mar 13, 2015Sep 17, 2015Novartis AgAntibody molecules to lag-3 and uses thereofWO2015139046A1Mar 16, 2015Sep 17, 2015Genentech, Inc.Methods and compositions for secretion of heterologous polypeptidesWO2015143156A1Mar 19, 2015Sep 24, 2015Bristol-Myers Squibb CompanyStabilized fibronectin based scaffold moleculesWO2015148531A1Mar 24, 2015Oct 1, 2015Genentech, Inc.Cancer treatment with c-met antagonists and correlation of the latter with hgf expressionWO2015149077A1Mar 30, 2015Oct 1, 2015Xencor, Inc.Bispecific antibodies that bind to cd38 and cd3WO2015153513A1Mar 30, 2015Oct 8, 2015Genentech, Inc.Anti-ox40 antibodies and methods of useWO2015153514A1Mar 30, 2015Oct 8, 2015Genentech, Inc.Combination therapy comprising anti-angiogenesis agents and ox40 binding agonistsWO2015155694A1Apr 8, 2015Oct 15, 2015Prothena Biosciences LimitedBlood-brain barrier shuttles containing antibodies recognizing alpha-synucleinWO2015164665A1Apr 23, 2015Oct 29, 2015Genentech, Inc.Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumabWO2015179658A2May 21, 2015Nov 26, 2015Genentech, Inc.Anti-gpc3 antibodies and immunoconjugatesWO2015179835A2May 22, 2015Nov 26, 2015Genentech, Inc.Mit biomarkers and methods using the sameWO2015191986A1Jun 12, 2015Dec 17, 2015Genentech, Inc.Methods of treating and preventing cancer drug resistanceWO2015195917A1Jun 18, 2015Dec 23, 2015Mersana Therapeutics, Inc.Monoclonal antibodies against her2 epitope and methods of use thereofWO2016001485A1Jun 26, 2015Jan 7, 2016Glykos Finland OySaccharide derivative of a toxic payload and antibody conjugates thereofWO2016007235A1May 29, 2015Jan 14, 2016Genentech, Inc.Anti-pd-l1 antibodies and diagnostic uses thereofWO2016007775A1Jul 9, 2015Jan 14, 2016Genentech, Inc.Notch pathway inhibitionWO2016014846A1Jul 23, 2015Jan 28, 2016Moderna Therapeutics, Inc.Modified polynucleotides for the production of intrabodiesWO2016014984A1Jul 24, 2015Jan 28, 2016Xencor, Inc.Rapid clearance of antigen complexes using novel antibodiesWO2016024195A1Aug 7, 2015Feb 18, 2016Novartis AgAnti-cdh6 antibody drug conjugatesWO2016033570A1Aug 28, 2015Mar 3, 2016Juno Therapeutics, Inc.Antibodies and chimeric antigen receptors specific for cd19WO2016036804A1Sep 2, 2015Mar 10, 2016Immunogen, Inc.Cytotoxic benzodiazepine derivativesWO2016040856A2Sep 11, 2015Mar 17, 2016Genentech, Inc.Cysteine engineered antibodies and conjugatesWO2016040868A1Sep 11, 2015Mar 17, 2016Genentech, Inc.Anti-cll-1 antibodies and immunoconjugatesWO2016040880A1Sep 11, 2015Mar 17, 2016Novartis AgCombination therapies of alk inhibitorsWO2016040892A1Sep 11, 2015Mar 17, 2016Novartis AgCombination therapiesWO2016044396A1Sep 16, 2015Mar 24, 2016Genentech, Inc.Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepinesWO2016054315A1Oct 1, 2015Apr 7, 2016Medimmune, LlcMethod of conjugating a polypeptideWO2016054555A2Oct 2, 2015Apr 7, 2016Novartis AgCombination therapiesWO2016057841A1Oct 8, 2015Apr 14, 2016Novartis AgCompositions and methods of use for augmented immune response and cancer therapyWO2016061142A1Oct 13, 2015Apr 21, 2016Novartis AgAntibody molecules to pd-l1 and uses thereofWO2016061389A2Oct 15, 2015Apr 21, 2016Genentech, Inc.Anti-alpha-synuclein antibodies and methods of useWO2016070062A2Oct 30, 2015May 6, 2016Genentech, Inc.Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using sameWO2016073157A1Oct 15, 2015May 12, 2016Genentech, Inc.Anti-ang2 antibodies and methods of use thereofWO2016073378A1Nov 2, 2015May 12, 2016Genentech, Inc.Assays for detecting t cell immune subsets and methods of use thereofWO2016075670A1Nov 13, 2015May 19, 2016Novartis AgAntibody drug conjugatesWO2016077381A1Nov 10, 2015May 19, 2016Genentech, Inc.Anti-interleukin-33 antibodies and uses thereofWO2016081639A1Nov 18, 2015May 26, 2016Genentech, Inc.Antibodies against bace1 and use thereof for neural disease immunotherapyWO2016081640A1Nov 18, 2015May 26, 2016Genentech, Inc.Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of useWO2016081643A1Nov 18, 2015May 26, 2016Genentech, Inc.Anti-transferrin receptor antibodies and methods of useWO2016081748A2Nov 19, 2015May 26, 2016Bristol-Myers Squibb CompanyAntibodies against cd73 and uses thereofWO2016086021A1Nov 24, 2015Jun 2, 2016Bristol-Myers Squibb CompanyNovel pd-l1 binding polypeptides for imagingWO2016090157A1Dec 3, 2015Jun 9, 2016Celgene CorporationBiomolecule conjugatesWO2016090210A1Dec 4, 2015Jun 9, 2016Genentech, Inc.ANTI-CD79b ANTIBODIES AND METHODS OF USEWO2016094566A2Dec 9, 2015Jun 16, 2016Genentech, Inc.Blood brain barrier receptor antibodies and methods of useWO2016100882A1Dec 18, 2015Jun 23, 2016Novartis AgCombination therapiesWO2016115559A1Jan 18, 2016Jul 21, 2016Juno Therapeutics, Inc.Antibodies and chimeric antigen receptors specific for ror1WO2016117346A1Jan 22, 2016Jul 28, 2016Chugai Seiyaku Kabushiki KaishaA combination of two or more anti-c5 antibodies and methods of useWO2016141230A1Mar 3, 2016Sep 9, 2016Sirenas LlcCyclic peptide analogs and conjugates thereofWO2016141387A1Mar 7, 2016Sep 9, 2016Xencor, Inc.Modulation of t cells with bispecific antibodies and fc fusionsWO2016144608A1Mar 1, 2016Sep 15, 2016Bristol-Myers Squibb CompanyAntibodies conjugatable by transglutaminase and conjugates made therefromWO2016150899A2Mar 21, 2016Sep 29, 2016Bayer Pharma AktiengesellschaftAnti-ceacam6 antibodies and uses thereof* Cited by examinerClassifications U.S. Classification424/181.1, 530/388.15, 530/388.9, 530/388.8, 540/462, 514/229.5, 530/391.7International ClassificationA61K31/535, A61K47/48Cooperative ClassificationA61K47/48384, A61K31/535European ClassificationA61K31/535, A61K47/48T2CLegal EventsDateCodeEventDescriptionSep 30, 1996FPAYFee paymentYear of fee payment: 4Sep 28, 2000FPAYFee paymentYear of fee payment: 8Oct 29, 2004FPAYFee paymentYear of fee payment: 12May 13, 2008ASAssignmentOwner name: IMMUNOGEN, INC., MASSACHUSETTSFree format text: ADDRESS CHANGE;ASSIGNOR:IMMUNOGEN, INC.;REEL/FRAME:020930/0905Effective date: 20080324Owner name: IMMUNOGEN, INC.,MASSACHUSETTSFree format text: ADDRESS CHANGE;ASSIGNOR:IMMUNOGEN, INC.;REEL/FRAME:020930/0905Effective date: 20080324RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services

value: This website is a search engine provided by Google. Handling over 3.5 billion searches per day, it has a 92% share of the global search engine market.


text:
Words containing borgswe | Words that contain borgswe
http://www.thefreedictionary.com/words-containing-borgswe
Dictionary, Encyclopedia and Thesaurus - The Free Dictionary 10,131,207,911 visitors served
Words containing borgswe
Found 1 words containing borgswe. Browse our Scrabble Word Finder, Words With Friends cheat dictionary, and WordHub word solver to find words that contain borgswe. Or use our Unscramble word solver to find your best possible play! Related: Words that start with borgswe
9 letter words containing borgsweSee also
9 letter words containing borgswe
Words containing borgsw
Words containing borgswee

type: global

value: This website is an American online dictionary and encyclopedia that aggregates information from various sources.